Genetic and Pharmacologic Manipulation of TLR4 Has Minimal Impact on Ethanol Consumption in Rodents

R. Adron Harris,¹ Michal Bajo,² Richard L. Bell,³ Yuri A. Blednov,¹ Florence P. Varodayan,² Jay M. Truitt,¹ Giordano de Guglielmo,² Amy W. Lasek,⁴ Marian L. Logrip,² Leandro F. Vendruscolo,² Amanda J. Roberts,⁵ Edward Roberts,⁶ Olivier George,² Jody Mayfield,¹ Timothy R. Billiar,⁷ David J. Hackam,⁷ R. Dayne Mayfield,¹ George F. Koob,² Marisa Roberto,² and Gregg E. Homanics⁸

¹Waggoner Center for Alcohol and Addiction Research, The University of Texas at Austin, Austin, Texas 78712, ²Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, California 92037, ³Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, Indiana 46202, ⁴Department of Psychiatry, University of Illinois, Chicago, Illinois 60612, ⁵Molecular and Cellular Neuroscience Department and Mouse Behavioral Assessment Core, The Scripps Research Institute, La Jolla, California 92037, ⁶Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, ⁷Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, and ⁸Departments of Anesthesiology and Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261

Toll-like receptor 4 (TLR4) is a critical component of innate immune signaling and has been implicated in alcohol responses in preclinical and clinical models. Members of the Integrative Neuroscience Initiative on Alcoholism (INIA-Neuroimmune) consortium tested the hypothesis that TLR4 mediates excessive ethanol drinking using the following models: (1) *Tlr4* knock-out (KO) rats, (2) selective knock-down of *Tlr4* mRNA in mouse nucleus accumbens (NAc), and (3) injection of the TLR4 antagonist (+)-naloxone in mice. Lipopolysaccharide (LPS) decreased food/water intake and body weight in ethanol-naïve and ethanol-trained wild-type (WT), but not *Tlr4* KO rats. There were no consistent genotypic differences in two-bottle choice chronic ethanol intake or operant self-administration in rats before or after dependence. In mice, (+)-naloxone did not decrease drinking-in-the-dark and only modestly inhibited dependence-driven consumption at the highest dose. *Tlr4* knockdown in mouse NAc did not decrease drinking in the two-bottle choice continuous or intermittent access tests. However, the latency to ethanol-induced loss of righting reflex increased and the duration decreased in KO versus WT rats. In rat central amygdala neurons, deletion of *Tlr4* altered GABA_A receptor function, but not GABA release. Although there were no genotype differences in acute ethanol effects before or after chronic intermittent ethanol exposure, genotype differences were observed after LPS exposure. Using different species and sexes, different methods to inhibit TLR4 signaling, and different ethanol consumption tests, our comprehensive studies indicate that TLR4 may play a role in ethanol-induced sedation and GABA_A receptor function, but does not regulate excessive drinking directly and would not be an effective therapeutic target.

Key words: (+)-naloxone; chronic intermittent ethanol vapor; drinking-in-the-dark; lipopolysaccharide; operant self-administration; Toll-like receptor 4 knock-out

Significance Statement

Toll-like receptor 4 (TLR4) is a key mediator of innate immune signaling and has been implicated in alcohol responses in animal models and human alcoholics. Members of the Integrative Neuroscience Initiative on Alcoholism (INIA-Neuroimmune) consortium participated in the first comprehensive study across multiple laboratories to test the hypothesis that TLR4 regulates excessive alcohol consumption in different species and different models of chronic, dependence-driven, and binge-like drinking. Although TLR4 was not a critical determinant of excessive drinking, it was important in the acute sedative effects of alcohol. Current research efforts are directed at determining which neuroimmune pathways mediate excessive alcohol drinking and these findings will help to prioritize relevant pathways and potential therapeutic targets.

Introduction

Gene expression studies have shown strong representation of immune- and inflammatory-related genes in brains from human

alcoholics and rodents after chronic alcohol treatment (Liu et al., 2006; Robinson et al., 2014; Crews and Vetreno, 2016). Deletion of immune genes reduced alcohol consumption in mice and pro-

Received June 20, 2016; revised Oct. 7, 2016; accepted Dec. 1, 2016.

Author contributions: R.A.H., M.B., R.L.B., Y.A.B., A.J.R., O.G., R.D.M., G.F.K., M.R., and G.E.H. designed research; M.B., R.L.B., Y.A.B., F.P.V., J.M.T., G.d.G., M.L.L., L.F.V., A.J.R., and M.R. performed research; A.W.L., E.R., T.R.B., and

D.J.H. contributed unpublished reagents/analytic tools; M.B., R.L.B., Y.A.B., F.P.V., J.M.T., G.d.G., L.F.V., A.J.R., J.M., R.D.M., and M.R. analyzed data; R.A.H., M.B., R.L.B., Y.A.B., J.M.T., G.d.G., A.J.R., J.M., R.D.M., G.F.K., M.R., and G.E.H. wrote the paper.

vided corroborating behavioral validation for several immune mediators that were predicted by the genomic studies (Blednov et al., 2012; Mayfield et al., 2013). In addition, alcohol craving and consumption were positively correlated with elevated plasma levels of inflammatory cytokines in human alcoholics (Leclercq et al., 2012; Leclercq et al., 2014) and immune marker expression in human postmortem brain was correlated with total lifetime alcohol consumption and age of drinking onset (Crews and Vetreno, 2016).

Current research efforts are focused on determining which neuroimmune/inflammatory pathways are important for mediating excessive alcohol drinking. The family of Toll-like receptors (TLRs), in particular TLR4, is a major component of innate immune signaling and has been hypothesized to mediate inflammatory effects of alcohol in the brain (Alfonso-Loeches et al., 2010; Szabo and Lippai, 2014; Alfonso-Loeches et al., 2016). TLR4 activation is triggered through pathogen-derived ligands, such as the bacterial endotoxin lipopolysaccharide (LPS) and endogenous ligands including high mobility group box 1 protein (Vezzani et al., 2011). Acute ethanol exposure activates TLR4 signaling in brain astrocytes and microglia (Blanco et al., 2005; Fernandez-Lizarbe et al., 2013) and chronic ethanol also triggers TLR4-mediated neuroimmune responses (Lippai et al., 2013; Pascual et al., 2015; Alfonso-Loeches et al., 2016).

Some studies have suggested a role for TLR4 in ethanol drinking, although this has not been observed consistently. Systemic injection of LPS (a primary TLR4 ligand) increased voluntary ethanol consumption in mice (Blednov et al., 2011) and elevated plasma levels of LPS, along with increased intestinal permeability, were measured in human alcoholics (Leclercq et al., 2012). Selective knockdown of TLR4 in the CeA or the ventral tegmental area (VTA) (but not the ventral pallidum, VP) decreased binge drinking in alcohol-preferring (P) rats (Liu et al., 2011; June et al., 2015). Although TLR4 deficiency protected against ethanol-induced glial activation and induction of inflammatory mediators, *Tlr4* knock-out (KO) mice did not differ from wild-type (WT) mice in chronic ethanol consumption (Alfonso-Loeches et al., 2010; Pascual et al., 2011). The TLR4 antagonist T5342126 decreased drinking and the density of a microglial protein in the CeA in ethanol-dependent and nondependent mice, but the decreased drinking was apparently due to nonspecific effects (Bajo et al., 2016). Overall, there is strong evidence for activation of TLR4 and other neuroimmune mediators in chronic ethanol exposure, but a direct causal link between TLR4 and alcohol drinking behavior has not been shown.

Members of the Integrative Neuroscience Initiative on Alcoholism (INIA-Neuroimmune) consortium (<http://www.inia-west.org/>) participated in extensive multidisciplinary studies

to test the hypothesis that TLR4 is directly involved in ethanol drinking and other ethanol-related responses. TLR4 signaling was inhibited using the following: (1) null mutant rats lacking the *Tlr4* gene, (2) selective knockdown of *Tlr4* mRNA in the nucleus accumbens (NAc) of mice using Cre recombinase-mediated *Tlr4* gene excision, and (3) injection of the selective TLR4 antagonist (+)-naloxone in C57BL/6J mice. None of these approaches provided consistent evidence that TLR4 regulates ethanol intake in any drinking test in mice or rats. However, there was evidence that TLR4 mediates the acute sedative effects of ethanol. Electrophysiological studies revealed that genetic deletion of *Tlr4* did not alter spontaneous GABA release in rat CeA neurons, but altered the kinetics of GABA_A receptor-mediated IPSCs.

Materials and Methods

Animals

Rats. A rat line on a Wistar background harboring a nonfunctional *Tlr4* gene was produced using transcription activator-like effector nuclease mediated mutagenesis as described previously (Ferguson et al., 2013). This line carries a 13-base pair shift mutation in *Tlr4* Exon 1 and has a dramatically attenuated response to LPS challenge (Ferguson et al., 2013). Heterozygous breeding pairs were produced at the University of Pittsburgh (Pittsburgh, PA) and shipped to The Scripps Research Institute (La Jolla, CA) and the Indiana University School of Medicine (Indianapolis). WT control and homozygous KO (*Tlr4*^{−/−}) littermates produced from these heterozygous pairs were used at the respective institutions. Offspring were weaned at ~21 d of age and genotyped as described previously (Ferguson et al., 2013).

Mice. Male 12-week-old C57BL/6J mice (The Jackson Laboratory) were used to investigate the effects of (+)-naloxone on ethanol drinking. Mice were housed in groups of four before the drinking tests. Lights were on a reverse 12 h light/12 h dark cycle (lights on at 8:00 P.M.). These studies were conducted at The Scripps Research Institute.

Adult male mice with a floxed *Tlr4* gene (i.e., mice with *Tlr4* flanked by LoxP sites, denoted as *Tlr4*^{fl/fl}) were generated on a C57BL/6 background as described previously (Sodhi et al., 2012) and used for knockdown studies in the NAc. Original breeders were produced at the University of Pittsburgh and mating pairs were shipped to The University of Texas at Austin. Mice were group-housed 4–5 to a cage on a 12 h light/12 h dark cycle (lights on at 7:00 A.M.). Ethanol consumption tests began when the mice were at least 2 months old.

Rats and mice at the different institutions were housed in temperature- and humidity-controlled vivaria with water and food provided *ad libitum*. All vivaria are approved by the Association for Assessment and Accreditation of Laboratory Animal Care. All procedures adhered to the National Institutes of Health's *Guide for the Care and Use of Laboratory Animals* and were approved by the institutional animal care and use committees at each site.

LPS injections

Ethanol-naïve adult male *Tlr4* KO and WT rats ($n = 4$ per genotype) weighing 479–604 g at the beginning of the experiment were housed individually on a 12 h light/12 h dark cycle (lights on at 6:00 A.M.). Baseline body weight and food and water consumption were measured 24 h before LPS injection. Rats were injected intraperitoneally with 1 mg/kg LPS (L3024, *Escherichia coli* 0111:B4; Sigma-Aldrich) dissolved in saline 30 min before the start of the dark cycle. Immediately before injection and subsequently every 12 h for 7 d, body weight and food and water intake were measured. Seven to 10 d after a single LPS injection, *in vitro* electrophysiological experiments were performed to assess the acute ethanol effects on CeA GABAergic transmission.

For LPS effects on operant ethanol self-administration, adult male *Tlr4* KO and WT rats ($n = 5$ per genotype) weighing 350–375 g at the beginning of the experiment were housed in groups of two per cage in a temperature-controlled (22°C) vivarium on a 12 h light/12 h reversed dark-light cycle (lights on at 10:00 P.M.). After completing operant ethanol self-administration training (described below), the rats were housed individually, injected with LPS (1 mg/kg, i.p.), and body weight and food/water intake were recorded daily. Ethanol and water self-

This work was supported by the National Institutes of Health (Integrative Neuroscience Initiative on Alcoholism and the National Institute on Alcohol Abuse and Alcoholism Grants U01 AA013517 and AA013498 to M.R., Grants U24AA015512 and U01 AA013522 to R.L.B., Grant U01 AA013520 to Y.A.B. and R.A.H., Grants U01 AA020926 and P0 AA020683 to R.D.M., Grants U01 AA013523 and AA020893 to A.J.R., Grant AA016654 to A.W.L., and Grant U01 AA020889 to G.E.H.). (G.F.). We thank Jillian Benavidez, Mendy Black, Molly Brennan, Carolyn Ferguson, Tali Nadav, Lindsay Cates, and Donghong He for expert technical assistance and Brigitte Kieffer and Jahan Dadgar for providing the EGFP-Cre construct.

The authors declare no competing financial interests.

M.L. Logrip's present address: Department of Psychology, Indiana University–Purdue University Indianapolis, IN. L.F. Vendruscolo's present address: National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Bethesda, MD.

G.F. Koob's present address: National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD.

Correspondence should be addressed to R. Adron Harris, Ph.D., Waggoner Center for Alcohol and Addiction Research, The University of Texas at Austin, 2500 Speedway, Austin, TX 78712. E-mail: harris@austin.utexas.edu.

DOI:10.1523/JNEUROSCI.2002-16.2016

Copyright © 2017 the authors 0270-6474/17/371140-17\$15.00/0

administration testing were performed in 30 min sessions for 14 consecutive days followed by a second LPS injection and 14 more days of testing. Baseline body weight and food and water consumption were measured 24 h before the first LPS injection.

LPS data are presented as the mean $\pm$ SEM intake in 24 h (food, water) or the percentage change relative to preinjection baseline (body weight). Raw data (intake or body weight change, in grams, over a 24 h period) were analyzed using two-way repeated-measures ANOVA with group (*Tlr4* KO vs WT) as the between-subjects factor and days since LPS injection as the within-subjects factor. Bonferroni and Newman–Keuls tests were used for *post hoc* analyses.

Ethanol intake tests in rats

Two-bottle choice (2BC). Rats were double-housed by sex and genotype (*Tlr4* KO vs WT). Lights were on a reverse 12 h light/12 h dark cycle (lights on at 10:30 P.M.). On postnatal day 85, male and female rats were transferred from their home cages and singly housed in hanging stainless steel wire-mesh cages for habituation to this environment. Male and female littermate offspring of each genotype were tested using the 2BC ethanol consumption test beginning on postnatal day 90. Rats were given *ad libitum* choice access to 10% ethanol (v/v) and water for 5 weeks. Ethanol (grams per kilogram body weight) and water (milliliters per kilogram body weight) consumption were assessed 5 d/week and body weight (kilograms) was measured 3 d/week. Ethanol intake was converted to grams of absolute (i.e., corrected for specific gravity) ethanol consumed/kilogram of body weight/day. Due to daily fluctuations in ethanol consumption in all groups, the data for each day were averaged across each week of access. The weekly data were submitted to a $3 \times 2 \times 5$ (genotype by sex by week) mixed-model ANOVA, with genotype and sex as the between-subjects factors and week as the within-subjects factor.

Operant self-administration. Adult male *Tlr4* KO ($n = 12$) and WT ($n = 13$) rats weighing 250–350 g at the beginning of the experiment were housed in groups of two per cage in a temperature-controlled (22°C) room on a reverse 12 h light/12 h dark cycle and the behavioral tests were conducted during the dark phase of the circadian cycle. Self-administration sessions were conducted in standard operant conditioning chambers (Med Associates). Animals were first trained to self-administer 10% ethanol (w/v) and water solutions until stable responses were maintained. The rats were subjected to an overnight session in the operant chambers with access to 1 lever (right lever) that delivered water [fixed ratio 1 (FR1) schedule of reinforcement, i.e., each operant response was reinforced with 0.1 ml of the solution]. Food was available *ad libitum* during training. After 1 d off, the rats were subjected to a 2 h session (FR1) for 1 d and a 1 h session (FR1) the next day, with 1 lever delivering ethanol (right lever). All of the subsequent sessions lasted 30 min and 2 levers were available (left lever: water; right lever: ethanol) until stable levels of intake were reached. Upon completion of this procedure, the animals were allowed to self-administer 10% (w/v) ethanol and water (FR1). Self-administration was analyzed by two-way repeated-measures ANOVA with group as the between-subjects factor and session as the within-subjects factor.

Chronic intermittent ethanol (CIE). Rats were made dependent by chronic, intermittent exposure to ethanol vapor for 5–7 weeks as described previously (O'Dell et al., 2004; Gilpin et al., 2008). They underwent cycles of 14 h on [blood ethanol concentrations (BECs) during vapor exposure ranged between 150 and 250 mg%] and 10 h off, during which behavioral testing for acute withdrawal and operant self-administration (see below) occurred (i.e., 6–8 h after vapor was turned off when brain and BECs are negligible; Gilpin et al., 2009). In this model, rats exhibit somatic withdrawal signs and negative emotional symptoms reflected by anxiety-like responses and elevated brain reward thresholds (Schulteis et al., 1995; Roberts et al., 2000; Valdez et al., 2002; Rimondini et al., 2003; O'Dell et al., 2004; Sommer et al., 2007; Zhao et al., 2007; Edwards et al., 2012; Vendruscolo and Roberts, 2014). For the electrophysiology experiments, the rats were kept in the vapor chambers until they were killed.

Operant self-administration during CIE vapor exposure. Behavioral testing occurred three times per week. The rats were tested for 10%

ethanol (and water) self-administration on an FR1 schedule of reinforcement in 30 min sessions. Operant self-administration on an FR1 schedule requires minimal effort by the animal to obtain the reinforcement and herein was considered a measure of intake. Ethanol self-administration data were analyzed by two-way repeated-measures ANOVA with group (*Tlr4* KO vs WT) as the between-subjects factor and session as the within-subjects factor. Because the same rats were used to measure predependent versus dependent ethanol self-administration, the number of lever presses for ethanol (last six sessions before ethanol vapor exposure) were averaged and compared with the average lever presses across six self-administration sessions during ethanol vapor exposure. Data were analyzed using two-way mixed models ANOVA with group as the between-subjects factor and time (predependent vs dependent) as the within-subjects factor.

Ethanol intake tests in mice

Drinking-in-the-dark (DID). The DID procedure is a binge-like drinking model, which capitalizes on the circadian rhythm in drinking and uses a discrete time of exposure to ethanol to optimize pharmacologically significant ethanol drinking (Rhodes et al., 2005; Rhodes et al., 2007; Thiele et al., 2014). Three factors are important in this model: (1) providing access to ethanol a few hours into the dark cycle, (2) not allowing access to water when ethanol is offered, and (3) using genetically predisposed mice. BECs in C57BL/6J mice in this model are reliably >100 mg% after the final drinking period and motor impairments are detected using the accelerating rotarod and balance beam tests (Rhodes et al., 2005, 2007). C57BL/6J mice were individually housed 1 week before testing. On day 1, starting 3 h after lights off (11:00 A.M.), water bottles were replaced with drinking tubes containing 20% ethanol in tap water for 2 h. On day 4, the ethanol bottles remained for 4 h, with intakes recorded after both 2 and 4 h. Immediately after removal of the ethanol bottles, tail blood was sampled to measure BEC. On day 4, mice were injected with (+)-naloxone (0, 30, or 60 mg/kg; $n = 8$ per group) 30 min before the drinking session began (10:30 A.M.) to investigate its acute effects. The following week, saline or 60 mg/kg (+)-naloxone ($n = 8$ per group) was injected on all 4 d of DID testing 30 min before the drinking sessions to examine subchronic effects. (+)-Naloxone was synthesized by E.R. and freshly dissolved in saline and administered intraperitoneally at 0.01 ml/g body weight. The μ -opioid inactive stereoisomer, (+)-naloxone, is a selective TLR4 inhibitor (Hutchinson et al., 2008; Wang et al., 2016). Data were analyzed separately at the 2 and 4 h time points using one-way ANOVA with (+)-naloxone dose as the between-subjects factor.

CIE-2BC. In the CIE-2BC model, excessive ethanol consumption is observed after 2BC limited-access periods are cycled with chronic passive exposure to ethanol vapor in rats (Vendruscolo and Roberts, 2014) or C57BL/6J mice (Becker and Lopez, 2004; Finn et al., 2007; Griffin et al., 2009). This has been used to model the motivational aspects of alcohol dependence and the excessive drinking associated with the addicted state. For 15 d (5 d per week for 3 weeks), 30 min before the lights turn off (7:30 A.M.), C57BL/6J mice were individually housed for 2 h with access to 2 drinking tubes containing either 15% ethanol or water. Ethanol and water consumption during these 2 h periods were recorded. After this baseline period, mice were divided, based on equal ethanol and water consumptions, into two balanced groups to be exposed to CIE or air in identical vapor chambers. After baseline 2BC drinking, the CIE group was injected with 1.75 g/kg ethanol plus 68 mg/kg pyrazole (alcohol dehydrogenase inhibitor) and placed in the chambers to receive intermittent vapor for 4 d (vapor on for 16 h and off for 8 h). After each 16 h period of vapor, mice were removed and, on the second and fourth days, tail blood was sampled to determine BEC. Target BECs were 175–250 mg%. After the fourth day of exposure, mice were allowed 72 h of undisturbed time and were then given 5 d of 2 h access to bottles containing 15% ethanol and water to measure ethanol drinking and preference after vapor exposure. The control group was injected with 68 mg/kg pyrazole in saline and placed in chambers delivering air for the same periods as the CIE group and received 2BC testing at the same time as the ethanol vapor group. The vapor/air exposure and 5 d of 2BC testing were repeated for a total of 4 rounds of vapor and 2BC testing before (+)-naloxone testing. For the first study, 30 mice ($n = 15$ per group) were administered (+)-

naloxone (0, 3, 10, 30, 60 mg/kg) in a within-subjects manner 30 min before 2BC testing (7:00 A.M.). Drug injections were given every 3–4 d. For the second study, 20 mice were used in a between-subject design ($n = 4–6$ in 4 groups: control-vehicle, control-60 mg/kg (+)-naloxone, CIE-vehicle, CIE-60 mg/kg (+)-naloxone). Mice were injected 30 min before the 2BC procedure across 4 d of testing. Data from the first study were analyzed by two-way repeated-measures ANOVA (group as the between factor; dose as the within factor) and data from the second study were analyzed by three-way repeated-measures ANOVA (group and dose as the between factors; day as the within factor). Significant effects were further investigated using Fisher's protected (P)LSD tests.

2BC (24 h continuous access). Four weeks after lentiviral Cre-recombinase injections in the NAc to knock down *Tlr4* selectively (see below), a 2BC protocol was performed as described previously (Blednov et al., 2003). *Tlr4*^{F/F} male mice were allowed to acclimate for 1 week to individual housing. Two drinking bottles (containing water and ethanol) were available continuously to each mouse and bottles were weighed daily. Bottle positions were changed daily to control for position preferences. Mice were weighed every 4 d. After 4 d of water consumption (both bottles contained water), mice were offered 3% ethanol (v/v) versus water for 4 d. The amount of ethanol consumed (g/kg body weight per 24 h) was calculated for each mouse and these values were averaged for every concentration of ethanol. Immediately after 3% ethanol, a choice between 6% ethanol and water was offered for 2 d, followed by 8%, 10%, 12%, 14%, and finally 16% (v/v) ethanol (each concentration was offered for 4 d). Throughout the experiment, evaporation/spillage estimates were calculated daily using two bottles (containing water or the appropriate ethanol solution) placed in an empty cage. Data were analyzed by two-way repeated-measures ANOVA followed by Bonferroni *post hoc* tests.

2BC (24 h intermittent access). Intermittent (every other day) access to ethanol increases voluntary ethanol consumption in mice (Melendez, 2011). This drinking paradigm was tested in a different group of *Tlr4*^{F/F} male mice 4 weeks after lentivirus injections in the NAc. Mice were given access to a bottle of 15% (v/v) ethanol and a bottle of water during 24 h sessions every other day. The placement of the ethanol bottles was alternated with each drinking session to control for side preferences. The quantity of ethanol consumed was calculated as grams per kilogram body weight per 24 h. Evaporation/spillage estimates were calculated daily from two bottles (containing water or 15% ethanol solution) placed in an empty cage. Data were analyzed by two-way repeated-measures ANOVA followed by Bonferroni *post hoc* tests.

Acute behavioral effects

Ethanol-induced loss of righting reflex (LORR). Adult male *Tlr4* KO and WT rats ($n = 10$ per genotype) weighing 350–400 g were housed in groups of two per cage. Each rat was handled 5 min/d for 1 week before beginning the experiment. On test day, the rats were injected with 4 g/kg ethanol (20% v/v in saline, i.p.). After injection, the rat was placed in a supine position on a V-shaped platform. The time to LORR (time between the injection and the moment in which the rat is not able to right himself) and the time of LORR (interval between the loss of ability to flip over onto all four limbs when placed in a supine position and the time when this reflex was successfully demonstrated three consecutive times within 60 s) were scored. Data were analyzed using an unpaired *t* test.

Selective knockdown of TLR4 in mouse NAc

Lentivirus-mediated knockdown of *Tlr4*. *Tlr4*^{F/F} male mice received bilateral injections into the NAc with either a vesicular stomatitis virus (VSV-G) pseudotyped lentivirus expressing Cre recombinase fused to an enhanced green fluorescent protein (EGFP) under the control of a cytomegalovirus (CMV) promoter (LV-Cre-EGFP) or an "empty" VSV-G pseudotyped lentivirus vector expressing only the EGFP transgene under a CMV promoter (LV-EGFP-Empty). Virus was produced as described previously (Lasek et al., 2007). Mice were anesthetized by isoflurane inhalation, placed in a model 1900 stereotaxic apparatus (Kopf Instruments), and administered preoperative analgesic (Rimadyl, 5 mg/kg). The skull was exposed and bregma and lambda visualized with a dissecting microscope. A digitizer attached to the micromanipulator of the

Figure 1. *Tlr4* KO rats are resistant to LPS-induced toxicity. LPS produced transient reduction of food (A) and water (B) intake in male WT but not *Tlr4* KO rats. The data are presented as mean $\pm$ SEM food and water intake (in grams) in 24 h periods. Day 0 represents intake measured during the 24 h before LPS (1 mg/kg, i.p.) injection. C, LPS induced a robust weight loss in WT but not *Tlr4* KO rats. The data are presented as percentage change relative to preinjection baseline weight (error bars are obscured by the symbols). Data were analyzed by two-way repeated-measures ANOVA followed by Bonferroni *post hoc* tests; $*p < 0.05$, $**p < 0.01$, $***p < 0.001$ compared with baseline; $n = 4$ per genotype. Arrows indicate injection of LPS (1 mg/kg, i.p.).

stereotaxic apparatus was used to locate coordinates relative to bregma. Burr holes were drilled bilaterally above the injection sites in the skull using a drill equipped with a #75 carbide bit (Kopf Instruments). The injection sites targeted the NAc using the following coordinates relative to bregma: anteroposterior (AP) +1.49 mm, mediolateral (ML) ± 0.9 mm, and dorsoventral (DV) -4.8 mm. Injections were performed using a Hamilton 10 μ l microsyringe (model 1701) and a 30-gauge needle. The needle tip was lowered to the DV coordinate and retracted 0.2 mm. The

Figure 2. *Tlr4* KO rats trained to self-administer ethanol (10%) are resistant to LPS-induced toxicity. The data are presented as mean $\pm$ SEM of food (A) and water (B) intake in 24 h in male WT ($n = 5$) and *Tlr4* KO ($n = 5$) rats. Day 0 corresponds to intake for the 24 h before LPS (1 mg/kg, i.p.) injection. C, Time course of the change in body weight over 24 h in male rats. The data are presented as the percentage change relative to the preinjection baseline weight measured before the first LPS injection. D, Time course of the change in body weight of LPS-treated WT and KO rats after the first and second LPS injections. LPS-induced changes in body weight are expressed as the percentage change relative to the most recent preinjection weight. In WT rats, paired Student's t test ($t_{(4)} = 6.0$, $p < 0.01$) showed a significant decrease in loss of body weight 1–4 d after the second LPS injection ($-3.4 \pm 0.5\%$) compared with the weight loss after the first LPS injection ($-7.1 \pm 0.7\%$). There was no significant difference in the LPS effects between the first and second LPS injections in the *Tlr4* KO rats. Arrows indicate injection of LPS (1 mg/kg, i.p.).

Figure 3. LPS induces transient reduction in ethanol (10%) self-administration in WT but not *Tlr4* KO rats. Effect of LPS injections on ethanol (A) and water (B) self-administration in male WT and *Tlr4* KO rats. The data are presented as mean $\pm$ SEM lever presses during 30 min sessions. Baseline (BL) was calculated as the average of the last 4 sessions before each LPS injection. Rats were given two LPS (1 mg/kg, i.p.) injections 14 d apart and the data from both injections were averaged. The average lever presses 1–4 d and 5–12 d after LPS are shown. Data were analyzed by mixed-factorial ANOVA followed by Newman–Keuls *post hoc* test; $*p < 0.05$ compared with KO; $n = 5$ per genotype.

viral solution (1.0 μ l with titer of $\sim 3 \times 10^7$ pg gag antigen/ml in PBS, PBS) was injected into each site at a rate of 200 nl per min. After each injection, the syringe was left in place for 5 min before being retracted over a period of 3 min. Incisions were closed with tissue adhesive (Vetbond; 3M). Mice were housed individually after surgery and given a 4-week recovery period before starting the ethanol drinking tests. Separate groups of mice were used for each 2BC test.

RNA isolation. Approximately half of the treated *Tlr4*^{F/F} mice were killed within 24 h of completing the drinking tests. The brains were quickly removed, flash frozen in liquid nitrogen, and later frozen in optimal cutting temperature medium (VWR) in isopentane on dry ice and stored at -80°C . Brains were transferred to a cryostat set at -6°C for at least 1 h before sectioning. Sections (300 μ m) were collected from +1.80 to +0.60 mm (AP) relative to bregma and transferred to glass

slides that had been precooled on dry ice. Microdissection punches were performed on a frozen stage (-25°C) using a dual fluorescent protein flashlight (Nightsea) and the stereotaxic atlas of Paxinos and Franklin (2004) to confirm EGFP expression and the anatomical location of the injection site, respectively. Microdissection punches (Stoelting) with an inner diameter of 0.75 mm were used to obtain samples of NAc core and shell. This inner diameter corresponded to the viral spread around the injection site and minimized contamination from other tissue. Punches were taken bilaterally from four 300 μ m sections and stored at -80°C until RNA extraction. All equipment and surfaces involved in the collection of tissue were treated with 100% ethanol and RNaseZap (Life Technologies) to prevent RNA degradation. Total RNA was extracted using the MagMAX-96 for Microarrays Total RNA Isolation Kit (Life Technologies) according to the manufacturer's instructions. Yields and purity were assessed using a NanoDrop 8000 (Thermo Fisher Scientific), and quality of the total RNA preparation was determined using the Agilent 2200 TapeStation.

Quantitative real-time PCR. To verify *Tlr4* mRNA knockdown, single-stranded cDNA was synthesized from total RNA using the TaqMan High Capacity RNA-to-cDNA kit (Life Technologies). After reverse transcription, quantitative real-time PCR (qPCR) was performed in triplicate using TaqMan Gene Expression Assays together with the TaqMan Gene Expression Master Mix (Life Technologies) per the manufacturer's instructions. The TaqMan Gene Expression assays used were *Tlr4* (Mm00445273_m1) and enhanced GFP (Mr04097229_mr). *Gapdh* (Mm99999915_g1) was used as a reference gene and relative mRNA levels were determined using the $2^{-\Delta\Delta\text{CT}}$ method (Schmittgen and Livak, 2008). *Gapdh* was used as the endogenous control because of its stable expression across samples. Reactions were performed in a CFX384 Real-Time PCR Detection System (Bio-Rad) and data collected using Bio-Rad CFX Manager.

Target site verification. The other half of the *Tlr4*^{F/F}-treated mice were killed within 24 h of completing the drinking tests and transcardially perfused with PBS, pH 7.4, followed by 4% paraformaldehyde (PFA). Brains were harvested, postfixed for 24 h in 4% PFA at 4°C , and cryoprotected for 24 h in 20% sucrose in PBS at 4°C . Brains were placed in molds containing optimal cutting temperature compound (VWR) and frozen in isopentane on dry ice. The brains were equilibrated in a -12 to -14°C cryostat (Thermo Fisher Scientific) for at least 1 h and coronal 40 μ m sections of the NAc were placed in sterile PBS. Serial sections (40 μ m) of NAc (AP +2.00 to 0.00 mm) were mounted on slides with DAPI mounting medium (Vector Laboratories) and visualized using a Zeiss Axiovert 200M Fluorescent Microscope equipped with a 10 $\times$ objective to assess the location of the injection site. Quality of injection was scored quantitatively based on the strength of EGFP viral expression, injection location relative to target, and the spread of the virus. The injection was considered on target if the virus covered at least one-third of the NAc.

Whole-cell voltage-clamp electrophysiology

Slice preparation. Male WT and *Tlr4* KO rats (used previously for operant self-administration testing) were made ethanol dependent by CIE vapor

Figure 4. There was no effect of genotype on ethanol self-administration in WT or *Tlr4* KO rats before or after dependence. **A**, Male WT and *Tlr4* KO rats do not differ in ethanol (10%) self-administration before ethanol vapor exposure. The data are presented as mean $\pm$ SEM lever presses during 30 min sessions. Data were analyzed by two-way repeated-measures ANOVA with group as the between-subjects factor and session as the within-subjects factor. **B**, Male WT and *Tlr4* KO rats do not differ in ethanol (10%) self-administration after CIE exposure. Ethanol-dependent rats underwent cycles of 14 h on (BEC: 146.8 ± 3.6 mg/g) and 10 h off. The same rats were used to measure predependent versus postdependent ethanol self-administration. For baseline, the number of lever presses for ethanol (last six sessions before ethanol vapor exposure) was averaged and compared with the average number of lever presses over six self-administration sessions during CIE exposure. The data are presented as mean $\pm$ SEM lever presses during 30 min sessions. Data were analyzed using two-way ANOVA with group as the between-subjects factor and time (predependent vs dependent) as the within-subjects factor ($n = 8$ for WT and $n = 7$ for KO, $*p < 0.05$ compared with baseline).

exposure as described earlier and kept in the vapor chambers until time for electrophysiological studies. BECs were measured once or twice per week by tail bleeding and again before euthanasia. The mean BEC of all ethanol-exposed animals was 173.0 ± 21 mg/dl. Slices were prepared from 14 naive control, CIE WT, and *Tlr4* KO rats (425–595 g) as described previously (Gilpin et al., 2011; Cruz et al., 2012). Briefly, rats were anesthetized using 3–5% isoflurane, rapidly decapitated, and the brains placed in ice-cold high-sucrose solution, pH 7.3–7.4, containing the following (in mM): sucrose (206), KCl (2.5), CaCl_2 (0.5), MgCl_2 (7), NaH_2PO_4 (1.2), NaHCO_3 (26), glucose (5), and HEPES (5). Coronal brain slices (300 μm) were cut on a vibrating microtome (Leica VT1000S) and transferred to an oxygenated (95% O_2 /5% CO_2) artificial CSF (aCSF) solution containing the following (in mM): NaCl (130), KCl (3.5), CaCl_2 (2), NaH_2PO_4 (1.25), MgSO_4 (1.5), NaHCO_3 (24), and glu-

cose (10). Slices were incubated (30 min; 35–37°C) and then equilibrated at room temperature for 30 min. For each recording, a slice was placed in a recording chamber mounted on the stage of an upright microscope (Olympus BX50WI) and perfused (2–5 ml/min) with continuously oxygenated aCSF at room temperature.

Electrophysiological recording. Medial subdivision CeA neurons ($n = 84$) were visualized using infrared differential interference contrast (IR-DIC) optics, a CCD camera (EXi Aqua and ROLERA-XR; QImaging; Gilpin et al., 2011; Cruz et al., 2012) and a w60 or w40 water-immersion objective (Olympus Scientific Solutions). Recordings were performed in a gap-free acquisition mode with a sampling rate per signal of 10 kHz and low-pass filtered at 10 kHz using a Multiclamp 700B amplifier and Digi-data 1440A and pClamp 10 software (Molecular Devices). Borosilicate glass patch pipettes (3–6 M Ω) (Warner Instruments) were filled with an internal solution containing the following (in mM): KCl (145), EGTA (5), MgCl_2 (5), HEPES (10), Na-ATP (2), and Na-GTP (0.2). Spontaneous IPSCs (sIPSCs) mediated by GABA $_A$ receptors were isolated by adding glutamate receptor blockers 6,7-dinitroquinoxaline-2,3-dione (DNQX, 20 μM ; Tocris Bioscience) and DL-2-amino-5-phosphonovaleate (AP-5, 30 μM ; Tocris Bioscience) and the GABA $_B$ receptor antagonist CGP55845A (1 μM ; Sigma-Aldrich) directly to the aCSF. GABAergic miniature IPSCs (mIPSCs) were isolated using glutamatergic and GABA $_B$ receptor blockers and 0.5 μM tetrodotoxin (Biotum). All drugs were applied by bath superfusion.

Cells were clamped at -60 mV and recordings showing a series resistance >15 M Ω or a $>20\%$ change in series resistance, as monitored with a 10 mV pulse, were excluded. s/mIPSC frequency, amplitude, and kinetics were analyzed using semiautomated threshold-based mini detection software (Mini Analysis; Synaptosoft) and inspected visually. Only s/mIPSCs with amplitude >5 pA were accepted for analysis and final averages of s/mIPSC characteristics were derived from a minimum time interval of 2–5 min. GraphPad Prism 5.0 software was used for all statistical analyses. The s/mIPSC data were evaluated with cumulative probability analysis and statistical significance was determined using the Kolmogorov–Smirnov nonparametric two-sample test (Van der Kloot, 1991), with $p < 0.05$ considered significant. To assess whether differences in ethanol's effects on s/mIPSCs result from the treatment (naive, ethanol-dependent, and LPS-injected) and/or genotype (WT and *Tlr4* KO rats), two-way ANOVAs of the normalized values were performed (mean values of s/mIPSC characteristics during ethanol application divided by the baseline values). When appropriate, Bonferroni *post hoc* tests were used to assess significance between treatments. All data are presented as mean $\pm$ SEM and n refers to the number of neurons. One to five neurons were recorded per animal and all electrophysiological measures were obtained by pooling data from at least three animals per experimental group.

Results

Lack of LPS effects in *Tlr4* KO rats

***Tlr4* KO ethanol-naive rats are resistant to LPS-induced toxicity**
We monitored reductions in food intake (anorexia), water intake (adipsia), and body weight as signs of LPS-induced “sickness-like” behavior (McCarthy et al., 1984; Cross-Mellor et al., 2000; van Heesch et al., 2013) in naive and ethanol self-administering *Tlr4* KO and WT rats. Baseline measures of body weight or food and water consumption did not differ in KO and WT rats. In naive rats, LPS (1 mg/kg, i.p.) caused a transient reduction of food intake in WT, but not *Tlr4* KO rats (Fig. 1A). There were significant main effects of LPS ($F_{(7,42)} = 60.7$, $p < 0.0001$) and genotype ($F_{(1,42)} = 13.7$, $p < 0.01$) on food intake and an interaction between the factors ($F_{(7,42)} = 30.2$, $p < 0.001$). Profound anorexia occurred within 24 h after injection in WT rats, which persisted for at least 48 h (28.1 ± 2.0 g consumed 24 h before LPS vs 1.2 ± 0.8 g after LPS). WT rats gradually increased their food intake, reaching pre-LPS consumption levels by the sixth postinjection day (25.8 ± 3.4 g). In *Tlr4* KO rats, LPS caused a transient reduction in food intake (from 27.6 ± 3.7 g to 22.9 ± 3.2 g) after 24 h, followed by increased food intake on the fourth postinjection day (34.2 ± 1.5 g).

Figure 5. 2BC ethanol intake in male and female WT and *Tlr4* KO rats. **A**, Ethanol (10%) intake (g/kg/24 h), **B**, water intake (ml/kg/24 h), **C**, ethanol preference, and **D**, body weight (g) in male and female WT and *Tlr4* KO rats during 2BC drinking sessions measured over 5 weeks. The data are presented as mean $\pm$ SEM. Data were analyzed using $2 \times 2 \times 5$ (genotype by sex $\times$ week) mixed ANOVAs (WT male, $n = 23$; WT female, $n = 16$; KO male, $n = 15$; KO female, $n = 11$). *Significant ($p < 0.05$) difference between male and female rats within genotype; #significant ($p < 0.05$) difference between week 1 and a subsequent week for the respective sex within genotype.

LPS reduced water intake in WT rats only (Fig. 1B); this effect peaked on the second postinjection day, with drinking levels returning to baseline by the fourth postinjection day. There were main effects of LPS on water intake ($F_{(7,42)} = 7.1$, $p < 0.001$) and a significant interaction between LPS and genotype ($F_{(7,42)} = 4.8$, $p < 0.001$), but the main effect of genotype did not reach significance ($p = 0.05$). Reductions in food and water intake in WT rats were accompanied by significant weight loss, a pattern not observed in KO rats. LPS produced weight loss in WT rats during the first 3 postinjection days, reaching a peak loss of 10% body weight (Fig. 1C) (main effects of LPS ($F_{(7,42)} = 88.2$, $p < 0.001$) and genotype ($F_{(7,42)} = 79.6$, $p < 0.001$) and an interaction between the factors ($F_{(7,42)} = 73.6$, $p < 0.001$). Body weight then stabilized and the resumption of food intake was associated with the reappearance of normal diurnal fluctuations in body weight when measured every 12 h, similar to *Tlr4* KO rats (data not shown). Although a slight reduction in body weight was also observed in the 24–48 h after LPS injection in *Tlr4* KO rats, its magnitude was $<25\%$ of that observed in WT ($\sim 2.5\%$ absolute weight loss). The resistance of *Tlr4* KO rats to LPS-induced “sickness-like behavior” provides behavioral and functional validation that the *Tlr4* gene had been deleted.

Tlr4 KO rats trained to self-administer ethanol are resistant to LPS-induced toxicity

Similar to naive rats, there were no significant differences in baseline body weight or water and food intake in the WT and *Tlr4* KO rats trained to self-administer 10% ethanol. LPS injections (14 d apart) significantly ($p < 0.001$) reduced food intake in WT but not KO ethanol-trained rats (Fig. 2A). Two-way repeated-measures ANOVA showed main effects of LPS ($F_{(4,32)} = 63.9$, $p < 0.001$) and genotype ($F_{(1,32)} = 8.4$, $p < 0.05$) on food intake, as well as an interaction between the factors ($F_{(4,32)} = 43.8$, $p < 0.001$). Al-

though water intake was reduced after both LPS injections in WT rats, the intake over the 4 d period after LPS was reduced significantly only after the first injection (Fig. 2B), suggesting the development of tolerance to its effects. There were no effects of LPS injections on water intake in *Tlr4* KO rats. There were main effects of LPS on water consumption ($F_{(4,32)} = 5.1$, $p < 0.001$) and an interaction between LPS and genotype ($F_{(4,32)} = 4.0$, $p < 0.001$) without a main effect of genotype.

In WT rats, two LPS injections induced a significant loss in body weight measured over a 4 d period after each injection (Fig. 2C). Two-way repeated-measures ANOVA showed main effects of LPS ($F_{(4,32)} = 35.8$, $p < 0.001$) and genotype ($F_{(1,32)} = 68.4$, $p < 0.001$) and an interaction between the factors ($F_{(4,36)} = 17.1$, $p < 0.001$). LPS injections had no effect on the body weight of *Tlr4* KO rats (Fig. 2C). Because there was not a full recovery in body weight after the first LPS injection in WT rats, we calculated LPS-induced loss in body weight by comparing the weight during days 1–4 after injection to the weight at the time of the most recent injection. The second LPS injection induced a significantly ($p < 0.05$) less pronounced reduction of body weight ($-3.4 \pm 0.5\%$ after the second LPS injection vs $-7.1 \pm 0.7\%$ after the first injection) and faster recovery in WT rats (Fig. 2D), suggesting the development of tolerance to its effects.

LPS induces a transient reduction in ethanol self-administration in WT, but not *Tlr4* KO rats

At the end of self-administration training, the baseline lever presses for 10% ethanol were 19.8 ± 6.6 for WT and 13.3 ± 4.1 for KO rats. LPS (1 mg/kg, i.p.) was injected 30 min before the next session and rats were tested for ethanol and water self-administration in 30 min sessions for 14 consecutive days, followed by a second LPS injection and 14 more days of testing. Data after both LPS injections were averaged. A mixed-factorial ANOVA with genotype (*Tlr4* KO vs WT) as the between-subjects factor and time point (baseline, 1–4 d post-LPS, and 5–14 d post-LPS) as the within-subjects factor showed a significant effect of time point ($F_{(1,8)} = 7.5$; $p < 0.01$) and genotype $\times$ time point interaction ($F_{(2,8)} = 5.6$; $p < 0.05$). A Newman–Keuls *post hoc* test showed that LPS treatment reduced operant responding for ethanol in the WT group ($p < 0.05$) for 4 consecutive days after the injections (Fig. 3A). No genotype differences were found 5–14 d after LPS injections. A mixed-factorial ANOVA of the water self-administration data showed a significant effect of time point ($F_{(1,8)} = 7.5$; $p < 0.01$), but no difference in the genotype $\times$ time point interaction (Fig. 3B).

Lack of evidence for a role of TLR4 in ethanol consumption

No genotype differences in ethanol self-administration by WT or *Tlr4* KO rats before or after dependence

Although there was no significant genotype effect on baseline responses in the ethanol self-administration test above, we compared operant responding before and after ethanol dependence specifically

in both genotypes. Figure 4A shows ethanol self-administration in WT and *Tlr4* KO rats before ethanol vapor exposure (predependence). Operant self-administration of 10% ethanol varied over time (session effect: $F_{(11,143)} = 3.3$, $p < 0.0005$), but there were no genotype or genotype $\times$ time differences. After CIE vapor exposure (after dependence), there were also no differences in self-administration, with both WT and *Tlr4* KO rats showing similar increases in intake ($F_{(1,13)} = 12.3$, $p < 0.005$; Fig. 4B).

2BC ethanol intake in male and female WT vs *Tlr4* KO rats

We then compared sexes and genotypes in a 2BC chronic drinking paradigm (WT: males, $n = 23$; females, $n = 16$; *Tlr4* KO: males, $n = 15$; females, $n = 11$). The omnibus mixed ANOVA of the ethanol-drinking data revealed a marginally significant 3-way (genotype $\times$ sex $\times$ week) interaction for 10% ethanol (v/v) intake ($F_{(4,244)} = 2.4$, $p = 0.05$). There was a significant two-way (sex $\times$ week) interaction ($F_{(4,244)} = 3.3$, $p = 0.01$) and a marginally significant main effect of sex ($F_{(1,61)} = 4.0$, $p = 0.05$). As seen in Figure 5A, female rats drank more ethanol initially than male rats. This effect was observed for the *Tlr4* KO rats only during the first week of ethanol access ($F_{(1,25)} = 11.7$, $p < 0.01$), whereas the WT rats displayed this effect across the first 3 weeks of ethanol access ($F_{(1,38)} > 4.5$, $p < 0.05$). There were also changes in ethanol intake across weeks; specifically, WT male rats displayed significant ($p < 0.05$) increases between week 1 versus week 4 and week 1 versus week 5, whereas *Tlr4* KO male rats displayed significant ($p < 0.05$) increases between week 1 versus week 2 and week 1 versus week 5. There was a significant decrease in ethanol intake by female *Tlr4* KO rats between weeks 1 and 2. The omnibus mixed ANOVA of the water-drinking data revealed a significant two-way (sex $\times$ week) interaction ($F_{(4,244)} = 8.5$, $p < 0.001$) and a significant main effect of week ($F_{(4,244)} = 6.7$, $p < 0.001$). As shown in Figure 5B, male rats initially drank more water than females, with the effect reaching significance ($p < 0.05$) in the WT, but not *Tlr4* KO, rats during week 1. In addition, a modest but significant ($p < 0.05$) increase across weeks was observed in both the female *Tlr4* KO (week 1 vs week 4 and week 1 vs week 5) and WT (week 1 vs week 3, week 1 vs week 4, and week 1 vs week 5) rats. The omnibus mixed ANOVA of the ethanol preference data revealed a significant two-way (sex $\times$ week) interaction ($F_{(4,244)} = 12.6$, $p < 0.001$) and significant main effects of week ($F_{(4,244)} = 2.9$, $p < 0.05$) and sex ($F_{(1,61)} = 22.4$, $p < 0.001$). However, the main effect of genotype regarding ethanol preference did not reach significance ($p = 0.06$). Female WT and KO rats displayed decreased ethanol preference across weeks 4–5 and 3–5, respectively, compared with the first week (Fig. 5C). The omnibus mixed ANOVA of the body weight data revealed a significant two-way (sex $\times$ week) interaction ($F_{(4,244)} = 8.5$, $p < 0.001$), along with significant main effects of week ($F_{(4,244)} = 6.7$, $p < 0.001$) and sex ($F_{(1,61)} = 505.5$, $p < 0.001$). As seen in Figure 5D, female rats weighed significantly less than male rats, with no differences observed for genotype.

No significant effect of (+)-naloxone on DID in C57BL/6J mice

We examined the effect of pharmacological inhibition of TLR4 signaling in mice using a binge-like drinking model. (+)-Naloxone treatment did not alter ethanol (20%) intake (Fig. 6A) or BEC measured on drinking day 4 of the DID test. There was no overall effect of (+)-naloxone at 2 h ($F_{(2,21)} = 1.4$, $p = 0.3$) or 4 h ($F_{(2,21)} = 0.1$, $p = 0.9$), nor was there an effect on BEC measured at 4 h ($F_{(2,21)} = 0.4$, $p = 0.7$). BECs for vehicle-treated, 30 mg/kg (+)-naloxone-treated, and 60 mg/kg (+)-naloxone-treated mice were 73.6 ± 13.7 , 80.8 ± 19.8 , and 58.2 ± 19.7 mg/dl, respectively. Administration of 60 mg/kg (+)-naloxone over 4 d also

Figure 6. Effect of (+)-naloxone on ethanol intake in the DID test in C57BL/6J mice. **A**, Male C57BL/6J mice were injected with (+)-naloxone (0, 30, or 60 mg/kg; $n = 8$ per group) 30 min before the start of the drinking session (20% ethanol) on day 4 of the DID protocol and intake was measured after 2 or 4 h. **B**, Male mice were injected with saline (vehicle) or 60 mg/kg (+)-naloxone 30 min before the start of the DID (20% ethanol) session for 4 d ($n = 8$ per group). The data are presented as mean $\pm$ SEM. Data were analyzed separately at the 2 and 4 h time points using one-way ANOVA with (+)-naloxone dose as the between-subjects factor.

Figure 7. Effect of (+)-naloxone on ethanol intake in the 2BC and CIE-2BC tests in C57BL/6J mice. **A**, Effect of individual doses of (+)-naloxone on 2BC intake (g/kg/2 h). Increased ethanol (15%) consumption was observed in the CIE-2BC group compared with the control 2BC group ($t_{(28)} = 5.8$, $p < 0.0001$). Male C57BL/6J mice ($n = 15$ per group) were administered (+)-naloxone (0, 3, 10, 30, 60 mg/kg) in a within-subject manner (every 3–4 d) 30 min before 2BC testing. The data are presented as mean $\pm$ SEM. Data were analyzed by two-way repeated-measures ANOVA (group as the between factor; dose as the within factor). **B**, Effect of 4 d of 60 mg/kg (+)-naloxone treatment on 2BC drinking (g/kg/2 h). The mice were then divided into two groups to receive (+)-naloxone or vehicle based on equal drinking averages. Male mice in a between-subject design ($n = 4–6$ per group: control-vehicle, control-60 mg/kg (+)-naloxone, CIE-vehicle, CIE-60 mg/kg (+)-naloxone) were injected 30 min before 2BC testing across 4 d. The data are presented as mean $\pm$ SEM. Data were analyzed by three-way repeated-measures ANOVA (group and dose as the between factors; day as the within factor). ** $p < 0.01$ compared with baseline.

had no significant effect on DID (Fig. 6B) or on BEC. There was a trend toward reduction of drinking by (+)-naloxone at 2 h ($F_{(1,14)} = 3.1$, $p = 0.1$), but not at 4 h ($F_{(1,14)} = 1.5$, $p = 0.2$). BECs measured at 4 h for vehicle- and 60 mg/kg (+)-naloxone-treated mice were 71.9 ± 21.2 and 41.9 ± 5.6 mg/dl, respectively, but the effect was not significant ($F_{(1,14)} = 1.9$, $p = 0.2$).

Effect of (+)-naloxone on 2BC and CIE-2BC drinking in C57BL/6J mice

We then tested the effect of individual injections of (+)-naloxone (3–60 mg/kg) in mice under conditions of 2BC excessive drinking after CIE exposure. BECs were 186.6 ± 7.2 , 149.6 ± 10.7 ,

Figure 8. Effect of *Tlr4* knockdown in NAc on ethanol intake in the continuous and intermittent access 2BC tests in *Tlr4*^{F/F} male mice. **A–C**, Ethanol intake (g/kg/24 h) (**A**), preference for ethanol (**B**), and total fluid intake (g/kg/24 h) (**C**) in the 2BC continuous access test in untreated control *Tlr4*^{F/F} mice ($n = 10$) and *Tlr4*^{F/F} mice injected with LV-Cre-EGFP ($n = 20$) or LV-Cre-Empty ($n = 10$). **D–F**, Ethanol (15%) intake (g/kg/24 h) (**D**), preference for ethanol (**E**), and total fluid intake (g/kg/24 h) (**F**) in the 2BC intermittent access test in untreated control *Tlr4*^{F/F} mice ($n = 10$) and *Tlr4*^{F/F} mice injected with LV-Cre-EGFP ($n = 20$) or LV-Cre-Empty ($n = 11$). Each point is the average of 2 d of drinking. The data are presented as mean $\pm$ SEM. Data were analyzed by two-way repeated-measures ANOVA.

Figure 9. Verification of injection site after *Tlr4* mRNA knockdown in NAc. **A**, Composite microscope image of a coronal section of the NAc after lentivirus injection using fluorescent microscopy (left) to show EGFP marker signal (green) and bright-field (right) to demonstrate neuroanatomy. **B**, Coronal brain atlas diagram of the NAc injection site with blue circles showing the NAc and green ovals illustrating the typical lentivirus location and spread.

174.8 $\pm$ 9.8, and 176.6 $\pm$ 9.0 mg/dl across the four cycles of vapor exposure. Increased ethanol (15%) drinking over 2 h was observed in the CIE-2BC group compared with the control 2BC group (Fig. 7A). An overall within-subjects ANOVA revealed a significant effect of group ($F_{(1,28)} = 30.5$, $p < 0.0001$) and a group $\times$ dose interaction ($F_{(4,112)} = 3.2$, $p < 0.05$). Further analysis revealed that this interaction was due to the decrease in ethanol intake by 60 mg/kg (+)-naloxone compared with vehicle

($p < 0.01$) and compared with 3 mg/kg ($p < 0.05$), 10 mg/kg ($p < 0.01$), and 30 mg/kg ($p < 0.01$) (+)-naloxone in the CIE group. There was no effect of (+)-naloxone in the control 2BC group. To further explore the high dose, we treated separate groups of control 2BC and CIE-2BC mice with 60 mg/kg (+)-naloxone for 4 d (Fig. 7B). There was a significant difference between 2BC and CIE-2BC mice in baseline drinking ($F_{(1,16)} = 23.2$, $p < 0.001$) after vapor exposure. These groups were each

divided into two subgroups to receive (+)-naloxone or vehicle based on equal drinking averages and equal BECs in the CIE-2BC groups. Vapor chamber BECs for the vehicle-treated mice were 165.7 ± 12.5 , 176.6 ± 3.2 , 176.6 ± 16.8 , and 214.9 ± 20.0 mg/dl and BECs for the 60 mg/kg (+)-naloxone-treated mice were 170.7 ± 14.1 , 187.9 ± 9.6 , 191.3 ± 9.1 , and 214.1 ± 14.4 mg/dl across the 4 cycles of exposure. Although the CIE effect was significant ($F_{(1,16)} = 30.2$, $p < 0.001$), there was no significant treatment effect ($F_{(1,16)} = 0.0005$, $p = 1.0$) or group $\times$ treatment interaction ($F_{(1,16)} = 0.2$, $p = 0.6$). Within-dose comparisons across injections also revealed no overall significant effects, but if each treatment day is compared with baseline, there was a significant effect of 60 mg/kg (+)-naloxone on day 3 ($p = 0.03$). However, drinking did not differ from vehicle-treated mice on this (or any other) day. These results support a modest but inconsistent effect of 60 mg/kg (+)-naloxone on ethanol drinking in dependent mice.

Effect of *Tlr4* mRNA knockdown in mouse NAc on 2BC drinking

Selective knockdown of TLR4 signaling in the CeA or VTA (but not the VP) decreased binge-like drinking in P rats (Liu et al., 2011; June et al., 2015). In the current study, we examined *Tlr4* knockdown in mouse NAc, another important brain region in binge drinking. However, knockdown in the NAc did not alter ethanol intake, preference for ethanol, or total fluid intake in the 24 h continuous access 2BC test in which *Tlr4*^{F/F} treated and untreated mice could drink either water or a series of increasing ethanol (3–16%) concentrations (Fig. 8A–C).

In the 2BC test with intermittent access to 15% ethanol, comparison of *Tlr4*^{F/F} treated (LV-EGFP-Cre; LV-EGFP-Empty) and control (untreated) mice revealed a significant treatment $\times$ day interaction for ethanol consumption ($F_{(6,174)} = 2.3$; $p < 0.05$), but not for ethanol preference or total fluid intake (Fig. 8D–F). Two-way repeated-measures ANOVA showed no main effect of treatment in any test. *Post hoc* analyses for each day when corrected for multiple comparisons also showed no significant differences between LV-EGFP-Cre versus LV-EGFP-Empty treated mice or between LV-EGFP-Cre treated versus control untreated mice. Although there was a trend toward increased alcohol consumption in the intermittent test after *Tlr4* mRNA knockdown in NAc, this was not statistically significant.

Verification of *Tlr4* knockdown in NAc

Verification of successful knockdown of *Tlr4* mRNA in the NAc involved a two-step process: (1) confirmation of needle placement and (2) quantitation of *Tlr4* mRNA. Half of the treated (LV-EGFP-Cre, LV-EGFP-Empty) *Tlr4*^{F/F} mice were used to verify injection coordinates. Figure 9A is a representative image of a coronal section of the NAc (AP +1.49 mm) from a lentivirus-treated *Tlr4*^{F/F} mouse. The left side is a fluorescent image that shows the EGFP signal (surrogate marker for lentivirus transduction) in green and DAPI (a stain that visualizes the nuclei of all cells) in blue. The right side of the image is a bright-field image used to better visualize the neuroanatomical landmarks. Figure 9B is a brain atlas image of a coronal section (AP +1.49 mm) showing the desired target coordinates, with the blue circles highlighting the NAc and the green ovals demonstrating the location of the LV-EGFP-Cre and LV-EGFP-Empty infection. All samples obtained from mice in both drinking experiments were on target and demonstrated an EGFP signal that covered at least one-third of the NAc.

Micropunches of the injection site were obtained from the other half of the treated (LV-EGFP-Cre, LV-EGFP-Empty)

Figure 10. Verification of *Tlr4* mRNA knockdown after lentivirus injections in NAc. *Tlr4* mRNA levels in the NAc target site were assessed by qPCR and normalized relative to *Gadph* mRNA levels after the 2BC continuous access ($n = 12$, LV-EGFP-Cre; $n = 7$, LV-EGFP-Empty) and 2BC intermittent access tests ($n = 11$, LV-EGFP-Cre; $n = 7$, LV-EGFP-Empty). Values (mean $\pm$ SEM) are shown relative to LV-EGFP-Empty treated mice; *** $p < 0.001$ determined by Student's *t* test.

Tlr4^{F/F} mice. The extracted RNA had excellent yields, purity, and quality; RNA integrity numbers averaged >8.0 , indicating little or no degradation, and the 260/230 and 260/280 ratios were >2.0 . We observed $>60\%$ knockdown ($p < 0.001$) of *Tlr4* mRNA relative to the endogenous control 8 weeks after injection in mice exposed to 2BC continuous and intermittent access drinking tests (Fig. 10).

Role of TLR4 in the acute behavioral actions of ethanol

Reduced duration of ethanol-induced LORR in *Tlr4* KO rats

Previous work in mice showed that lack of *Tlr4* or administration of (+)-naloxone reduced the duration of LORR induced by a single high dose of ethanol (4.5 g/kg) (Corrigan et al., 2015). We tested a single high dose of ethanol (4.0 g/kg) in rats and also found that the latency to induction of ethanol-induced LORR was significantly increased (Fig. 11A) and the duration of LORR was significantly reduced (Fig. 11B) in *Tlr4* KO rats compared with WT rats.

Role of TLR4 in GABAergic transmission in CeA neurons

Spontaneous GABAergic transmission

We examined GABAergic transmission in CeA neurons from *Tlr4* KO and WT rats based on the evidence for TLR4 pathway signaling in GABAergic synapses in mouse CeA (Bajo et al., 2014). The effect of an acute application of ethanol (44 mM) on GABAergic transmission was tested in CeA neurons of naive WT and *Tlr4* KO rats and after CIE or a single LPS challenge (experiments performed 7–10 d after LPS injection). We found no significant differences in the baseline s/mIPSC frequencies, amplitudes, or decay times in CeA neurons from WT and *Tlr4* KO mice (Table 1). However, we observed a significant ($p < 0.05$) difference in baseline mIPSC rise times between the genotypes (Table 1). In addition, whereas LPS and CIE treatments had no effect on s/mIPSC parameters across genotypes, both treatments significantly ($p < 0.05$) altered s/mIPSC rise times in WT and *Tlr4* KO mice (Table 1).

Acute ethanol application

We also compared the effects of acute ethanol application on GABAergic transmission in CeA neurons from naive WT and

Figure 11. The sedative effects of ethanol are reduced in *Tlr4* KO male rats. *Left panel*, Time to LORR in male WT and *Tlr4* KO rats ($n = 10$ per group, $df = 18$, $t = 2.3$, $p < 0.05$). *Right panel*, Time of LORR in WT and *Tlr4* KO rats ($n = 10$ per group, $df = 18$, $t = 3.9$, $p < 0.01$). The data are presented as mean $\pm$ SEM in minutes. * $p < 0.05$ and ** $p < 0.01$ determined by unpaired Student's t test.

Tlr4 KO rats. Ethanol (44 mM) significantly ($p < 0.01$ – 0.05) increased s/mIPSC frequencies in CeA neurons from both genotypes; ethanol increased the mean sIPSC frequency by $37.6 \pm 11.4\%$ in WT and $45.7 \pm 14.2\%$ in *Tlr4* KO rats (Fig. 12*A,B*) and increased the mIPSC frequency by $26.4 \pm 7.1\%$ in WT and $43.6 \pm 13.5\%$ in *Tlr4* KO rats (Fig. 13*C,D*). Acute ethanol did not alter s/mIPSC amplitudes or kinetics in CeA neurons from either genotype (Fig. 12). There was no significant difference in the acute ethanol-induced increases of CeA GABA release in neurons from naive WT and *Tlr4* KO rats.

CIE vapor exposure

In CeA neurons from CIE-treated WT and *Tlr4* KO rats, acute ethanol (44 mM) application also increased s/mIPSC frequencies (Fig. 13). Two-way repeated-measures ANOVA of the peak ethanol effects from all of the tested cells showed a significant main effect of ethanol ($F_{(1,16)} = 9.3$, $p < 0.05$), but no effect of genotype or interaction between ethanol and genotype. Ethanol significantly facilitated sIPSC frequencies in WT neurons by $57.2 \pm 4.3\%$, but had mixed effects in the CeA neurons from *Tlr4* KO rats. For example, ethanol enhanced sIPSC frequencies in only 6 of 10 *Tlr4* KO neurons (47% of control) and either decreased ($< 85\%$ of control, $n = 3$) or had no effect (85–115% of control, $n = 1$) in the remaining neurons. Although the magnitude of the acute ethanol effect on s/mIPSC frequencies was similar in CIE-treated and naive WT and *Tlr4* KO rats, the ethanol-induced facilitation of sIPSC frequency was transient (5–6 min) in the CIE-treated *Tlr4* KO rats compared with the other 3 groups (12–15 min; data not shown). Consistent, sustained ethanol-induced increases in mIPSC frequencies were observed in both WT and *Tlr4* KO neurons. Two-way repeated-measures ANOVA showed a significant main effect of ethanol ($F_{(1,9)} = 19.8$, $p <$

0.05), but not genotype or the interaction between ethanol and genotype. There were no significant acute ethanol-induced changes in the amplitude and kinetics of s/mIPSCs in CIE-treated WT and *Tlr4* KO rats.

LPS exposure

We investigated the effects of acute ethanol application on CeA neurons from WT and *Tlr4* KO rats 7–10 d after a single LPS injection (1 mg/kg, i.p.). There was a significant main effect of ethanol treatment ($F_{(1,13)} = 5.9$, $p < 0.05$), but not genotype, and no significant interaction between genotype and ethanol. Ethanol (44 mM) had

opposite effects on sIPSC frequency in WT versus *Tlr4* KO rats, represented by a significant reduction of $41.4 \pm 4.0\%$ in the LPS-treated WT neurons (Fig. 14). Although there was an overall significant increase of $29.9 \pm 21.6\%$ in sIPSC frequency by acute ethanol in neurons from LPS-treated *Tlr4* KO rats (Fig. 14), ethanol produced mixed, cell-specific effects; ethanol increased the frequencies in 3 of 7 cells ($> 115\%$ of control, $n = 3$), but had no effect (85–115% of control, $n = 4$) in the others. There were no significant ethanol-induced changes in the sIPSC amplitude and kinetics between the two groups.

Finally, we compared the normalized effects of acute ethanol on s/mIPSC frequencies across the different treatment groups using two-way ANOVA. There was a significant main effect of treatment ($F_{(2,46)} = 6.7$, $p < 0.01$), but not genotype ($F_{(2,46)} = 1.3$, $p > 0.05$), on sIPSC frequencies and a significant interaction between treatment and genotype ($F_{(2,46)} = 7.3$, $p < 0.01$). Bonferroni *post hoc* tests showed significant differences in ethanol effects in the LPS-treated rats compared with naive and CIE-treated WT rats, whereas there were no significant differences among the individual treatment groups of *Tlr4* KO rats. There were no main effects of treatment or genotype on acute ethanol-induced potentiation of mIPSC frequencies between naive and CIE-treated rats.

Discussion

INIA-Neuroimmune investigators used extensive behavioral and electrophysiological tests to examine the role of TLR4 in acute and chronic ethanol responses in rats and mice (summarized in Table 2). Different genetic and pharmacologic approaches were used to inhibit TLR4-mediated signaling and different

Table 1. Baseline spontaneous and miniature IPSCs in CeA neurons from naive, CIE-treated, and LPS-treated WT and *Tlr4* KO rats

Group	Spontaneous IPSCs				Miniature IPSCs			
	Frequency	Amplitude	Rise time**	Decay time	Frequency	Amplitude	Rise time***	Decay time
WT Naive	1.1 $\pm$ 0.4	79.6 $\pm$ 6.1	2.8 $\pm$ 0.1	8.7 $\pm$ 0.9	0.5 $\pm$ 0.1	52.7 $\pm$ 2.2	3.1 $\pm$ 0.2	7.1 $\pm$ 1.9
KO Naive	1.1 $\pm$ 0.4	78.9 $\pm$ 11.3	3.1 $\pm$ 0.2	9.1 $\pm$ 0.9	0.3 $\pm$ 0.1	56.8 $\pm$ 3.7	2.5 $\pm$ 0.1	5.6 $\pm$ 0.4
WT CIE	1.0 $\pm$ 0.4	65.2 $\pm$ 6.1	2.7 $\pm$ 0.1	8.5 $\pm$ 0.7	0.3 $\pm$ 0.1	46.6 $\pm$ 6.7	2.7 $\pm$ 0.2	5.6 $\pm$ 0.8
KO CIE	1.0 $\pm$ 0.4	80.2 $\pm$ 13.6	2.4 $\pm$ 0.2	8.7 $\pm$ 1.1	0.4 $\pm$ 0.1	58.8 $\pm$ 5.4	2.2 $\pm$ 0.1	6.1 $\pm$ 0.5
WT LPS	1.3 $\pm$ 0.3	98.9 $\pm$ 19.1	2.5 $\pm$ 0.1	10.6 $\pm$ 0.8	N/A	N/A	N/A	N/A
KO LPS	1.5 $\pm$ 0.6	70.7 $\pm$ 5.7	2.4 $\pm$ 0.1	8.6 $\pm$ 1.7	N/A	N/A	N/A	N/A

IPSCs in CeA neurons from naive rats (WT: $n = 13$; KO: $n = 12$), CIE-exposed rats (WT: $n = 8$; KO: $n = 10$), and ethanol-naive rats (WT: $n = 8$; KO: $n = 8$) injected with LPS (1 mg/kg, i.p.). Two-way ANOVA revealed no main effects of treatment, genotype, or the interaction of baseline frequencies, amplitudes, and decay times of the spontaneous IPSCs. There was a main effect of treatment ($F_{(2,53)} = 7.7$; $p < 0.01$) on the rise time, but no main effect of genotype or interaction between genotype and treatment. Likewise, there were no main effects of treatment or genotype and no interaction between treatment and genotype on the frequency, amplitude, and decay time of baseline miniature IPSCs from naive (WT: $n = 5$; KO: $n = 9$) and CIE-exposed (WT: $n = 5$; KO: $n = 6$) rats. However, there were significant main effects of treatment ($F_{(1,21)} = 7.4$, $p < 0.05$) and genotype ($F_{(1,21)} = 13.8$, $p < 0.01$) on baseline miniature IPSC rise time, but no interaction between genotype and treatment. Values are mean $\pm$ SEM.

* $p < 0.05$, ** $p < 0.01$, effect of treatment; *** $p < 0.01$, effect of genotype.

N/A, Not applicable.

Figure 12. Acute ethanol potentiates spontaneous and miniature GABA release in CeA neurons from ethanol-naïve WT and *Tlr4* KO rats. **A**, Traces of representative sIPSC recordings of CeA neurons from naïve WT (left) and *Tlr4* KO (right) male rats before and after acute bath application of ethanol (44 mM). **B**, Acute ethanol increased the mean sIPSC frequency in CeA neurons by $37.6 \pm 11.4\%$ in WT (from 1.4 ± 0.5 to 1.6 ± 0.6 Hz, $n = 9$) and by $45.7 \pm 14.2\%$ in KO (from 0.9 ± 0.2 to 1.2 ± 0.3 Hz, $n = 10$) rats. There was a significant main effect of ethanol ($F_{(1,17)} = 11.0$, $p < 0.01$), but no main effect of genotype or interaction between ethanol

models of voluntary ethanol intake were studied in male and female rodents.

In addition to genotyping, rats were injected with LPS to verify that TLR4, a primary target, was nonfunctional in the KO animals. LPS produced “sickness-like” behavior in naïve and ethanol-treated WT rats, represented by decreased food/water intake and body weight; however, *Tlr4* KO rats were resistant to these effects as reported previously in *Tlr4* KO mice (Qureshi et al., 1999; Kalis et al., 2003; von Meyenburg et al., 2004; Yang et al., 2014). We further demonstrated that WT ethanol-trained rats developed tolerance to LPS-induced toxicity in agreement with studies in ethanol-naïve rats (McCarthy et al., 1984; Cross-Mellor et al., 2000). Female B6 mice also showed evidence of tolerance to decreased body weight after a second LPS injection (Blednov et al., 2011).

LPS increased ethanol consumption in mice (Blednov et al., 2011) and elevated serum levels of LPS were positively correlated with alcohol craving in humans (Leclercq et al., 2012; Leclercq et al., 2014). In WT rats, LPS transiently reduced ethanol self-administration, but had no long-term effects on drinking in either genotype. The initial reduction in ethanol responding (1–4 d after LPS) may be due to induction of “sickness-like” behavior that affects the motivation for ethanol similar to effects on food/water intake. We found no differences in ethanol self-administration in WT and *Tlr4* KO rats before or after dependence and no consistent genotype differences in 2BC drinking over 5 weeks. The inconsistent decrease in dependence-driven drinking by 60 mg/kg (+)-naloxone may be due to nonspecific/aversive effects of this high dose, as reported in rats (Tanda et al., 2016).

TLR4 knockdown in the CeA or VTA decreased binge drinking in P rats (Liu et al., 2011; June et al., 2015). Given the prominent role of the NAc within the mesocorticolimbic reward circuit in alcohol abuse and dependence, we further studied the effects of TLR4 in this brain region. However, *Tlr4* mRNA knockdown in mouse NAc did not reduce 2BC continuous or limited access drinking. In addition to brain region, there are other key differences between the studies. We examined male C57BL/6J mice using the 2BC continuous and intermittent models, whereas the previous work was in P rats (the sex was not reported) using a binge-drinking model. The P rats had increased levels of GABA_A receptor $\alpha 2$ subunits and TLR4 in the CeA and VTA, and $\alpha 2$ subunit-specific knockdown in the CeA inhibited TLR4 function and decreased drinking (Liu et al., 2011). Furthermore, *Tlr4* knockdown in the CeA decreased $\alpha 2$ subunit expression and also reduced drinking (Liu et al., 2011). Therefore, the TLR4-related effects on binge drinking in P rats may be due to altered GABAergic ($\alpha 2$ subunit-specific) responses.

Although TLR4 signaling did not regulate ethanol consumption consistently in our rodent models or in other studies

and genotype. Acute ethanol did not have significant effects on sIPSC amplitudes (WT: $111.3 \pm 9.4\%$ of control; KO: $115.8 \pm 5.1\%$ of control) or kinetics (rise time: WT, $97.0 \pm 3.3\%$ of control; KO, $106.6 \pm 3.7\%$ of control; decay time: WT, $112.5 \pm 7.5\%$ of control; KO, $117.6 \pm 9.7\%$ of control). **C**, Representative mIPSCs recorded from CeA neurons of naïve WT and *Tlr4* KO rats showing an increase in mIPSC frequencies after acute ethanol application. **D**, Acute ethanol increased mIPSC frequencies in CeA WT and *Tlr4* KO neurons. There was a significant main effect of ethanol ($F_{(1,12)} = 11.8$, $p < 0.05$) on mIPSC frequencies in WT ($26.4 \pm 7.1\%$; from 0.5 ± 0.1 to 0.6 ± 0.1 Hz, $n = 5$) and KO neurons ($43.6 \pm 13.5\%$; from 0.3 ± 0.1 to 0.4 ± 0.1 Hz, $n = 9$), but no significant main effects of genotype or the interaction between ethanol and genotype. Ethanol had no effects on mIPSC amplitudes (WT: $100.3 \pm 2.0\%$ of control; KO: $93.6 \pm 3.6\%$ of control) or kinetics (rise time: WT, $90.9 \pm 2.8\%$ of control; KO, $99.9 \pm 4.9\%$ of control; decay time: WT, $102.9 \pm 2.3\%$ of control; KO, $96.7 \pm 11.6\%$ of control) in neurons from WT and *Tlr4* KO rats. Statistical significance was calculated by two-way repeated-measures ANOVA ($\#p < 0.05$). The data are presented as mean $\pm$ SEM.

Figure 13. Acute ethanol enhances GABA release in CeA neurons from WT and *Tlr4* KO rats differentially after CIE exposure. **A**, Traces of sIPSC recordings in CeA neurons from WT and *Tlr4* KO male rats exposed to CIE vapor. **B**, Bath application of 44 mM ethanol facilitated sIPSC frequencies in WT neurons significantly by $57.2 \pm 4.3\%$ (from 1.0 ± 0.4 to 1.5 ± 0.6 Hz, $n = 8$), but enhanced frequencies in only 6 of 10 KO neurons ($46.5 \pm 23.1\%$ of control; from 1.2 ± 0.7 to 1.7 ± 0.8 Hz, $n = 6$) and decreased ($< 85\%$ of control, $n = 3$) or had no effect ($85\text{--}115\%$ of control, $n = 1$) on sIPSC frequencies in the remainder ($85.5 \pm 9.3\%$ of control;

Figure 14. LPS injection alters GABA responses to acute ethanol in CeA neurons from WT but not *Tlr4* KO rats. **A**, Representative recordings of sIPSCs from LPS-treated WT and *Tlr4* KO male rats. **B**, Seven to 10 d after a single LPS injection (1 mg/kg, i.p.), acute 44 mM ethanol application reduced sIPSC frequencies by $41.4 \pm 4.0\%$ (from 1.3 ± 0.3 to 0.7 ± 0.2 Hz, $n = 8$) in CeA neurons from LPS-treated WT rats. Ethanol's effects on sIPSC frequencies in LPS-treated KO rats (an overall increase of $29.9 \pm 21.6\%$, $n = 7$) were more varied, with ethanol-induced potentiation ($> 115\%$ of control, $n = 3$) or no effect ($85\text{--}115\%$ of control, $n = 4$) occurring in a cell-specific manner. There was a significant main effect of ethanol treatment ($F_{(1,13)} = 5.9$, $p < 0.05$), but not genotype, and no interaction between genotype and ethanol. There were no significant effects of acute ethanol on the amplitudes (WT: $93.6 \pm 12.9\%$; KO: $112.3 \pm 11.1\%$ of control) or kinetics (rise time: WT, $109.9 \pm 4.4\%$; KO, $97.8 \pm 2.2\%$; decay time: WT, $90.2 \pm 14.7\%$; KO, $115.2 \pm 10.1\%$ of control) in LPS-treated WT and *Tlr4* KO rats. The data are presented as mean $\pm$ SEM. Statistical significance was calculated by two-way repeated-measures ANOVA ($\#p < 0.05$).

(Alfonso-Loeches et al., 2010; Pascual et al., 2011; Bajo et al., 2016; Blednov et al., 2017a), *Tlr4* KO rats displayed lower sensitivity than WT to the acute sedative effects of ethanol. This is consistent with results in mice lacking *Tlr4* or WT mice treated with (+)-naloxone (Wu et al., 2012b; Corrigan et al., 2015; Bled-

from 0.7 ± 0.1 to 0.5 ± 0.04 Hz) of KO neurons. Two-way repeated-measures ANOVA of the peak ethanol effects from all of the tested cells showed a significant main effect of ethanol ($F_{(1,16)} = 9.3$, $p < 0.05$), but no effect of genotype or interaction between ethanol and genotype. The acute ethanol effects on sIPSC frequencies were transient in the neurons from KO compared with WT rats. **C**, Representative mIPSCs in CeA neurons from WT and *Tlr4* KO rats chronically exposed to ethanol. **D**, Acute ethanol (44 mM) application increased mIPSC frequencies in WT and *Tlr4* KO neurons by $55.1 \pm 19.9\%$ (from 0.3 ± 0.1 to 0.4 ± 0.1 Hz, $n = 5$) and $58.6 \pm 22.6\%$ (from 0.4 ± 0.1 to 0.5 ± 0.8 Hz, $n = 6$), respectively. Two-way repeated-measures ANOVA showed a significant main effect of ethanol ($F_{(1,9)} = 19.8$, $p < 0.05$), but not genotype or the interaction between ethanol and genotype. Acute ethanol had no significant effects on the mean mIPSC amplitudes (WT: $104.8 \pm 6.9\%$ of control; KO: $109.9 \pm 11.3\%$ of control) or kinetics (rise time: WT, $105.4 \pm 5.8\%$ of control; KO, $112.0 \pm 6.2\%$ of control; decay time: WT, $115.1 \pm 13.3\%$ of control; KO, $101.4 \pm 4.3\%$ of control) in WT and *Tlr4* KO rats. The data are presented as mean $\pm$ SEM ($\#p < 0.05$).

Table 2. Summary of tests performed in rats and mice

Behavioral and electrophysiological tests in rats						
Groups	Body weight	Operant (30 min)	2BC (24 h)	LORR	Acute ethanol s/mlPSCs	
					Frequency	Amplitude/kinetics
WT vs <i>Tlr4</i> KO (naive)	—	— (10%)	— (10%) ^a	↑	—	—
WT vs <i>Tlr4</i> KO (CIE-treated)	—	— (10%)	—	—	—	—
WT vs <i>Tlr4</i> KO (LPS-treated)	↓	↓ 1–4 d (10%)	—	—	↓	—
Drinking tests in mice						
Groups	2BC (24 h)	2BC, CIE-2BC	DID (2,4 h)			
Control vs LV-EGFP-Cre <i>Tlr4</i> ^{fl/fl}	— (3–16%) — (15%, intermittent)	—	—			
Control vs (+)-naloxone (3–60 mg/kg)	—	— (15%) ^b	— (20%) ^b			
Control vs (+)-naloxone (60 mg/kg, 4 d)	—	— (15%) ^b	— (20%) ^b			

Overall changes in WT/control groups compared with *Tlr4* mutants or the TLR4 antagonist (+)-naloxone in ethanol drinking tests (ethanol concentrations are in parentheses) in rats and mice, ethanol (4 g/kg)-induced LORR in rats, and acute ethanol (44 mM)-induced s/mlPSCs in rat CeA neurons.

—, No significant difference between groups (control vs *Tlr4* mutants or control vs TLR4 antagonist treatment); ↑ and ↓, increased and decreased responses in WT vs KO rats, respectively.

^aNo consistent genotype differences across weeks.

^bDecreased ethanol consumption in 2BC-CIE mice at 60 mg/kg, but not consistently across studies (i.e., day 1 in within-subject study, but only day 3 in repeated treatment study).

nov et al., 2017b). A complex interaction between TLR2 and TLR4 in ethanol-induced LORR was reported (Corrigan et al., 2015) and ethanol also promoted physical TLR2/TLR4 interactions in lipid rafts, which may facilitate immune activation (Fernandez-Lizarbe et al., 2013). Therefore, a role for TLR signaling in ethanol-induced sedation is emerging across species and TLRs and associated pathways may regulate some of ethanol's acute responses synergistically.

We examined GABAergic transmission in CeA neurons because TLR4 pathway components were involved in ethanol's acute effects on GABAergic IPSPs in these synapses (Bajo et al., 2014) and because *Tlr4* knockdown in the CeA of P rats potentially reduced drinking via a GABAergic mechanism (Liu et al., 2011). Deletion of *Tlr4* did not affect baseline spontaneous GABA release in CeA neurons, but altered the kinetics of GABA_A receptor-mediated IPSCs, indicating a role for TLR4 in GABA_A receptor function (Otis et al., 1994). Generally, the kinetic properties of GABA_A-mediated currents are determined by subunit composition, posttranslational modifications, trafficking, synaptic localization, and clustering (Jacob et al., 2008; Wu et al., 2012a; Dixon et al., 2014) and we cannot exclude potential contributions from these factors.

Deletion of CD14, an accessory protein for LPS-mediated activation of TLR4, had no effects on CeA GABAergic transmission (Bajo et al., 2014), indicating different synaptic effects for different TLR4 pathway components. However, frequencies of sIPSCs and tonic currents were altered in *Il1rn* KO mice (Bajo et al., 2015). Collectively, our findings support distinct roles for neuroimmune regulators in basal GABAergic transmission.

Acute ethanol increased action potential-dependent and -independent GABA release in CeA neurons from naive and CIE-treated WT and *Tlr4* KO rats in agreement with previous studies (Roberto et al., 2003; Roberto et al., 2004; Gilpin et al., 2011; Cruz et al., 2013; Herman et al., 2013). The lack of differences in acute ethanol effects on spontaneous GABAergic transmission, especially in naive rats, agrees with our study suggesting that CD14 (rather than TLR4) is critical for ethanol effects in CeA neurons (Bajo et al., 2014). After LPS exposure, acute ethanol reduced CeA GABAergic transmission in WT but not *Tlr4* KO neurons. Previous work in mice showed that LPS reduced firing of VTA neurons and increased ethanol drinking (Blednov et al., 2011). Despite the synaptic changes in WT neurons observed 7–10 d

after LPS exposure, LPS did not alter ethanol self-administration in WT or *Tlr4* KO rats at this time point. Although our results support the involvement of the TLR4 pathway in regulating CeA GABA transmission, it is likely that other immune mediators released during LPS-induced peripheral and central immune activation contribute to the altered ethanol effects in WT synapses.

In *Tlr4* KO rats after CIE or LPS treatment, we observed cell-specific responses to acute ethanol similar to the variable ethanol effects in naive *Cd14* or *Il1rn* KO mice (Bajo et al., 2014; Bajo et al., 2015). Activation of peripheral immune responses is known to stimulate discrete CeA neurons (Day et al., 1999; Serrats et al., 2006). Overall, these findings point to distinct neuronal populations and circuits in the CeA whose basal activities or ethanol responses are regulated differentially by proinflammatory/neuroimmune molecules.

We used different methods to target TLR4 and different models of ethanol intake, but there was little evidence that TLR4 regulates drinking directly. In microglia, (+)-naloxone and (+)-naltrexone may block TLR4 downstream signaling preferentially via the TRIF-IRF3 pathway (Wang et al., 2016), indicating that they may not block all arms of TLR4 signaling. Given that there were no consistent differences in 2BC drinking and operant self-administration of ethanol between WT and *Tlr4* KO rats, it is unlikely that the lack of (DID and 2BC) or inconsistent (CIE-2BC) effect of (+)-naloxone is due to incomplete TLR4 inhibition, particularly at the 60 mg/kg dose. Collectively, our results in mice and rats are in agreement with studies showing that *Tlr4* KO and WT mice did not differ in ethanol consumption (Alfonso-Loeches et al., 2010; Pascual et al., 2011; Blednov et al., 2017a). Our (+)-naloxone results in mice are consistent with another TLR4 inhibitor that also decreased ethanol consumption nonspecifically in mice (Bajo et al., 2016). To date, only knockdown of *Tlr4* mRNA in the CeA or VTA of P rats decreased binge drinking and this was associated with $\alpha 2$ subunit-specific GABAergic signaling. However, there is now consistent evidence across species for a role of TLR4 in mediating the acute sedative effects of alcohol, which could be an indicator of overall sensitivity to alcohol and susceptibility to develop dependence.

TLR4 mediates ethanol-induced increases in brain cytokines/chemokines and neurodegeneration and inhibition of TLR4 prevents or reverses ethanol-induced neuroimmune responses (Fernandez-Lizarbe et al., 2009; Alfonso-Loeches et al., 2010; Zou

and Crews, 2014; Bajo et al., 2016). Chronic ethanol exposure may also disrupt the integrity of the blood–brain barrier via TLR4-dependent signaling (Rubio-Araiz et al., 2016). TLR4 was associated with cognitive impairment and anxiety-related behavior during ethanol withdrawal (Pascual et al., 2011; Pascual et al., 2015) and with synaptic remodeling and anxiety induced by binge drinking in adolescent mice (Montesinos et al., 2016). However, our comprehensive study using different species and sexes, different methods to inhibit TLR4, and different tests of chronic, dependence-driven, and binge-like consumption indicates that *Tlr4* is not a critical gene for regulating ethanol drinking and inhibition of TLR4 signaling alone would not be an effective therapeutic strategy. Ethanol promotes physical interactions between TLR4 and TLR2 (Fernandez-Lizarbe et al., 2013) and TLR4/TLR2 interactions were implicated in ethanol-induced sedation (Corrigan et al., 2015), which warrants consideration that TLR4 and other neuroimmune mediators may regulate ethanol responses synergistically. Analyses of the conserved cross-species gene networks in alcoholics and animal models exposed to chronic alcohol will help to prioritize immune/inflammatory pathways (and candidate drugs) with improved therapeutic potential for alcohol use disorders.

References

- Alfonso-Loeches S, Pascual-Lucas M, Blanco AM, Sanchez-Vera I, Guerri C (2010) Pivotal role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage. *J Neurosci* 30:8285–8295. [CrossRef Medline](#)
- Alfonso-Loeches S, Ureña-Peralta J, Morillo-Bargues MJ, Gómez-Pinedo U, Guerri C (2016) Ethanol-induced TLR4/NLRP3 neuroinflammatory response in microglial cells promotes leukocyte infiltration across the BBB. *Neurochem Res* 41:193–209. [CrossRef Medline](#)
- Bajo M, Madamba SG, Roberto M, Blednov YA, Sagi VN, Roberts E, Rice KC, Harris RA, Siggins GR (2014) Innate immune factors modulate ethanol interaction with GABAergic transmission in mouse central amygdala. *Brain Behav Immun* 40:191–202. [CrossRef Medline](#)
- Bajo M, Herman MA, Varodayan FP, Oleata CS, Madamba SG, Harris RA, Blednov YA, Roberto M (2015) Role of the IL-1 receptor antagonist in ethanol-induced regulation of GABAergic transmission in the central amygdala. *Brain Behav Immun* 45:189–197. [CrossRef Medline](#)
- Bajo M, Montgomery SE, Cates LN, Nadav T, Delucchi AM, Cheng K, Yin H, Crawford EF, Roberts AJ, Roberto M (2016) Evaluation of TLR4 inhibitor, T5342126, in modulation of ethanol-drinking behavior in alcohol-dependent mice. *Alcohol Alcoholism* 51:541–548. [CrossRef Medline](#)
- Becker HC, Lopez MF (2004) Increased ethanol drinking after repeated chronic ethanol exposure and withdrawal experience in C57BL/6 mice. *Alcohol Clin Exp Res* 28:1829–1838. [CrossRef Medline](#)
- Blanco AM, Vallés SL, Pascual M, Guerri C (2005) Involvement of TLR4/type I IL-1 receptor signaling in the induction of inflammatory mediators and cell death induced by ethanol in cultured astrocytes. *J Immunol* 175:6893–6899. [CrossRef Medline](#)
- Blednov YA, Walker D, Alva H, Creech K, Findlay G, Harris RA (2003) GABA receptor alpha 1 and beta 2 subunit null mutant mice: behavioral responses to ethanol. *J Pharmacol Exp Ther* 305:854–863. [CrossRef Medline](#)
- Blednov YA, Benavidez JM, Geil C, Perra S, Morikawa H, Harris RA (2011) Activation of inflammatory signaling by lipopolysaccharide produces a prolonged increase of voluntary alcohol intake in mice. *Brain Behav Immun* 25:S92–S105. [CrossRef Medline](#)
- Blednov YA, Black M, Chernis J, Da Costa A, Mayfield J, Harris RA (2017a) Ethanol consumption in mice lacking CD14, TLR2, TLR4, or MyD88. *Alcohol Clin Exp Ther*, in press.
- Blednov YA, Black M, Chernis J, Da Costa A, Mayfield J, Harris RA (2017b) Sedative and motor incoordination effects of ethanol in mice lacking CD14, TLR2, TLR4, or MyD88. *Alcohol Clin Exp Ther*, in press.
- Blednov YA, Ponomarev I, Geil C, Bergeson S, Koob GF, Harris RA (2012) Neuroimmune regulation of alcohol consumption: behavioral validation of genes obtained from genomic studies. *Addict Biol* 17:108–120. [CrossRef Medline](#)
- Corrigan F, Wu Y, Tuke J, Collier JK, Rice KC, Diener KR, Hayball JD, Watkins LR, Somogyi AA, Hutchinson MR (2015) Alcohol-induced sedation and synergistic interactions between alcohol and morphine: a key mechanistic role for Toll-like receptors and MyD88-dependent signaling. *Brain Behav Immun* 45:245–252. [CrossRef Medline](#)
- Crews FT, Vetreno RP (2016) Mechanisms of neuroimmune gene induction in alcoholism. *Psychopharmacology* 233:1543–1557. [CrossRef Medline](#)
- Cross-Mellor SK, Kent WD, Kavaliers M, Ossenkopp KP (2000) Examining the effects of lipopolysaccharide and cholecystokinin on water ingestion: comparing intake and palatability. *Brain Res* 861:220–232. [CrossRef Medline](#)
- Cruz MT, Herman MA, Kallupi M, Roberto M (2012) Nociceptin/orphanin FQ blockade of corticotropin-releasing factor-induced gamma-aminobutyric acid release in central amygdala is enhanced after chronic ethanol exposure. *Biol Psychiatry* 71:666–676. [CrossRef Medline](#)
- Cruz MT, Herman MA, Cote DM, Ryabinin AE, Roberto M (2013) Ghrelin increases GABAergic transmission and interacts with ethanol actions in the rat central nucleus of the amygdala. *Neuropsychopharmacology* 38:364–375. [CrossRef Medline](#)
- Day HE, Curran EJ, Watson SJ Jr, Akil H (1999) Distinct neurochemical populations in the rat central nucleus of the amygdala and bed nucleus of the stria terminalis: evidence for their selective activation by interleukin-1beta. *J Comp Neurol* 413:113–128. [Medline](#)
- Dixon C, Sah P, Lynch JW, Keramidas A (2014) GABAA receptor alpha and gamma subunits shape synaptic currents via different mechanisms. *J Biol Chem* 289:5399–5411. [CrossRef Medline](#)
- Edwards S, Guerrero M, Ghoneim OM, Roberts E, Koob GF (2012) Evidence that vasopressin V1b receptors mediate the transition to excessive drinking in ethanol-dependent rats. *Addict Biol* 17:76–85. [CrossRef Medline](#)
- Ferguson C, McKay M, Harris RA, Homanics GE (2013) Toll-like receptor 4 (Tlr4) knockout rats produced by transcriptional activator-like effector nuclease (TALEN)-mediated gene inactivation. *Alcohol* 47:595–599. [CrossRef Medline](#)
- Fernandez-Lizarbe S, Pascual M, Guerri C (2009) Critical role of TLR4 response in the activation of microglia induced by ethanol. *J Immunol* 183:4733–4744. [CrossRef Medline](#)
- Fernandez-Lizarbe S, Montesinos J, Guerri C (2013) Ethanol induces TLR4/TLR2 association, triggering an inflammatory response in microglial cells. *J Neurochem* 126:261–273. [CrossRef Medline](#)
- Finn DA, Snelling C, Fretwell AM, Tanchuck MA, Underwood L, Cole M, Crabbe JC, Roberts AJ (2007) Increased drinking during withdrawal from intermittent ethanol exposure is blocked by the CRF receptor antagonist D-Phe-CRF(12–41). *Alcohol Clin Exp Res* 31:939–949. [CrossRef Medline](#)
- Gilpin NW, Misra K, Koob GF (2008) Neuropeptide Y in the central nucleus of the amygdala suppresses dependence-induced increases in alcohol drinking. *Pharmacol Biochem Behav* 90:475–480. [CrossRef Medline](#)
- Gilpin NW, Smith AD, Cole M, Weiss F, Koob GF, Richardson HN (2009) Operant behavior and alcohol levels in blood and brain of alcohol-dependent rats. *Alcohol Clin Exp Res* 33:2113–2123. [CrossRef Medline](#)
- Gilpin NW, Misra K, Herman MA, Cruz MT, Koob GF, Roberto M (2011) Neuropeptide Y opposes alcohol effects on gamma-aminobutyric acid release in amygdala and blocks the transition to alcohol dependence. *Biol Psychiatry* 69:1091–1099. [CrossRef Medline](#)
- Griffin WC 3rd, Lopez MF, Yanke AB, Middaugh LD, Becker HC (2009) Repeated cycles of chronic intermittent ethanol exposure in mice increases voluntary ethanol drinking and ethanol concentrations in the nucleus accumbens. *Psychopharmacology* 201:569–580. [CrossRef Medline](#)
- Herman MA, Kallupi M, Luu G, Oleata CS, Heilig M, Koob GF, Ciccocioppo R, Roberto M (2013) Enhanced GABAergic transmission in the central nucleus of the amygdala of genetically selected Marchigian Sardinian rats: alcohol and CRF effects. *Neuropharmacology* 67:337–348. [CrossRef Medline](#)
- Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, Patel SJ, Crysdale NY, Harrison JA, Maier SF, Rice KC, Watkins LR (2008) Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). *Eur J Neurosci* 28:20–29. [CrossRef Medline](#)
- Jacob TC, Moss SJ, Jurd R (2008) GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition. *Nat Rev Neurosci* 9:331–343. [CrossRef Medline](#)
- June HL, Liu J, Warnock KT, Bell KA, Balan I, Bollino D, Puche A, Aurelian L

- (2015) CRF-amplified neuronal TLR4/MCP-1 signaling regulates alcohol self-administration. *Neuropsychopharmacology* 40:1549–1559. [CrossRef Medline](#)
- Kalis C, Kanzler B, Lembo A, Poltorak A, Galanos C, Freudenberg MA (2003) Toll-like receptor 4 expression levels determine the degree of LPS-susceptibility in mice. *Eur J Immunol* 33:798–805. [CrossRef Medline](#)
- Lasek AW, Janak PH, He L, Whistler JL, Heberlein U (2007) Downregulation of mu opioid receptor by RNA interference in the ventral tegmental area reduces ethanol consumption in mice. *Genes Brain Behav* 6:728–735. [CrossRef Medline](#)
- Leclercq S, Cani PD, Neyrinck AM, Stärkel P, Jamar F, Mikolajczak M, Delzenne NM, de Timary P (2012) Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects. *Brain Behav Immun* 26:911–918. [CrossRef Medline](#)
- Leclercq S, Matamoros S, Cani PD, Neyrinck AM, Jamar F, Stärkel P, Windey K, Tremaroli V, Bäckhed F, Verbeke K, de Timary P, Delzenne NM (2014) Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. *Proc Natl Acad Sci U S A* 111: E4485–E4493. [CrossRef Medline](#)
- Lippai D, Bala S, Csak T, Kurt-Jones EA, Szabo G (2013) Chronic alcohol-induced microRNA-155 contributes to neuroinflammation in a TLR4-dependent manner in mice. *PLoS One* 8:e70945. [CrossRef Medline](#)
- Liu J, Lewohl JM, Harris RA, Iyer VR, Dodd PR, Randall PK, Mayfield RD (2006) Patterns of gene expression in the frontal cortex discriminate alcoholic from nonalcoholic individuals. *Neuropsychopharmacology* 31: 1574–1582. [CrossRef Medline](#)
- Liu J, Yang AR, Kelly T, Puche A, Esoga C, June HL Jr, Elnabawi A, Merchanthaler I, Sieghart W, June HL Sr, Aurelian L (2011) Binge alcohol drinking is associated with GABAA α 2-regulated Toll-like receptor 4 (TLR4) expression in the central amygdala. *Proc Natl Acad Sci U S A* 108:4465–4470. [CrossRef Medline](#)
- Mayfield J, Ferguson L, Harris RA (2013) Neuroimmune signaling: a key component of alcohol abuse. *Curr Opin Neurobiol* 23:513–520. [CrossRef Medline](#)
- McCarthy DO, Kluger MJ, Vander AJ (1984) The role of fever in appetite suppression after endotoxin administration. *Am J Clin Nutr* 40:310–316. [Medline](#)
- Melendez RI (2011) Intermittent (every-other-day) drinking induces rapid escalation of ethanol intake and preference in adolescent and adult C57BL/6J mice. *Alcohol Clin Exp Res* 35:652–658. [CrossRef Medline](#)
- Montesinos J, Pascual M, Rodríguez-Arias M, Miñarro J, Guerri C (2016) Involvement of TLR4 in the long-term epigenetic changes, rewarding and anxiety effects induced by intermittent ethanol treatment in adolescence. *Brain Behav Immun* 53:159–171. [CrossRef Medline](#)
- O'Dell LE, Roberts AJ, Smith RT, Koob GF (2004) Enhanced alcohol self-administration after intermittent versus continuous alcohol vapor exposure. *Alcohol Clin Exp Res* 28:1676–1682. [CrossRef Medline](#)
- Otis TS, De Koninck Y, Mody I (1994) Lasting potentiation of inhibition is associated with an increased number of gamma-aminobutyric acid type A receptors activated during miniature inhibitory postsynaptic currents. *Proc Natl Acad Sci U S A* 91:7698–7702. [CrossRef Medline](#)
- Pascual M, Balaño P, Alfonso-Loeches S, Aragón CM, Guerri C (2011) Impact of TLR4 on behavioral and cognitive dysfunctions associated with alcohol-induced neuroinflammatory damage. *Brain Behav Immun* 25: S80–S91. [CrossRef Medline](#)
- Pascual M, Balaño P, Aragón CM, Guerri C (2015) Cytokines and chemokines as biomarkers of ethanol-induced neuroinflammation and anxiety-related behavior: role of TLR4 and TLR2. *Neuropharmacology* 89:352–359. [CrossRef Medline](#)
- Paxinos G, Franklin KBJ (2004) The mouse brain in stereotaxic coordinates. 4th Ed. Elsevier Science (USA).
- Qureshi ST, Larivière L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D (1999) Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (TLR4). *J Exp Med* 189:615–625. [CrossRef Medline](#)
- Rhodes JS, Best K, Belknap JK, Finn DA, Crabbe JC (2005) Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. *Physiol Behav* 84:53–63. [CrossRef Medline](#)
- Rhodes JS, Ford MM, Yu CH, Brown LL, Finn DA, Garland T Jr, Crabbe JC (2007) Mouse inbred strain differences in ethanol drinking to intoxication. *Genes Brain Behav* 6:1–18. [Medline](#)
- Rimondini R, Sommer W, Heilig M (2003) A temporal threshold for induction of persistent alcohol preference: behavioral evidence in a rat model of intermittent intoxication. *J Stud Alcohol* 64:445–449. [CrossRef Medline](#)
- Roberto M, Madamba SG, Moore SD, Tallent MK, Siggins GR (2003) Ethanol increases GABAergic transmission at both pre- and postsynaptic sites in rat central amygdala neurons. *Proc Natl Acad Sci U S A* 100:2053–2058. [CrossRef Medline](#)
- Roberto M, Madamba SG, Stouffer DG, Parsons LH, Siggins GR (2004) Increased GABA release in the central amygdala of ethanol-dependent rats. *J Neurosci* 24:10159–10166. [CrossRef Medline](#)
- Roberts AJ, Heyser CJ, Cole M, Griffin P, Koob GF (2000) Excessive ethanol drinking following a history of dependence: animal model of allostasis. *Neuropsychopharmacology* 22:581–594. [CrossRef Medline](#)
- Robinson G, Most D, Ferguson LB, Mayfield J, Harris RA, Blednov YA (2014) Neuroimmune pathways in alcohol consumption: evidence from behavioral and genetic studies in rodents and humans. *Int Rev Neurobiol* 118:13–39. [CrossRef Medline](#)
- Rubio-Araiz A, Porcu F, Perez-Hernandez M, Garcia-Gutierrez MS, Aracil-Fernandez MA, Gutierrez-Lopez MD, Guerri C, Manzanera J, O'Shea E, Colado MI (2016) Disruption of blood-brain barrier integrity in post-mortem alcoholic brain: preclinical evidence of TLR4 involvement from a binge-like drinking model. *Addict Biol*. In press.
- Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc* 3:1101–1108. [CrossRef Medline](#)
- Schulteis G, Markou A, Cole M, Koob GF (1995) Decreased brain reward produced by ethanol withdrawal. *Proc Natl Acad Sci U S A* 92:5880–5884. [CrossRef Medline](#)
- Serrats J, Sawchenko PE (2006) CNS activational responses to staphylococcal enterotoxin B: T-lymphocyte-dependent immune challenge effects on stress-related circuitry. *J Comp Neurol* 495:236–254. [CrossRef Medline](#)
- Sodhi CP, Neal MD, Siggers R, Sho S, Ma C, Branca MF, Prindle T Jr, Russo AM, Afrazi A, Good M, Brower-Sinning R, Firek B, Morowitz MJ, Ozolek JA, Gittes GK, Billiar TR, Hackam DJ (2012) Intestinal epithelial Toll-like receptor 4 regulates goblet cell development and is required for necrotizing enterocolitis in mice. *Gastroenterology* 143:708–718.e1–5. [CrossRef Medline](#)
- Sommer WH, Rimondini R, Marquitz M, Lidström J, Siems WE, Bader M, Heilig M (2007) Plasticity and impact of the central renin-angiotensin system during development of ethanol dependence. *J Mol Med* 85:1089–1097. [CrossRef Medline](#)
- Szabo G, Lippai D (2014) Converging actions of alcohol on liver and brain immune signaling. *Int Rev Neurobiol* 118:359–380. [CrossRef Medline](#)
- Tanda G, Mereu M, Hiranita T, Quarterman JC, Coggiano M, Katz JL (2016) Lack of specific involvement of (+)-naloxone and (+)-naltrexone on the reinforcing and neurochemical effects of cocaine and opioids. *Neuropsychopharmacology* 41:2772–2781. [CrossRef Medline](#)
- Thiele TE, Crabbe JC, Boehm SL 2nd (2014) “Drinking in the Dark” (DID): a simple mouse model of binge-like alcohol intake. *Curr Protoc Neurosci* 68:9.49.1–9.49.12. [CrossRef Medline](#)
- Valdez GR, Roberts AJ, Chan K, Davis H, Brennan M, Zorrilla EP, Koob GF (2002) Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. *Alcohol Clin Exp Res* 26:1494–1501. [CrossRef Medline](#)
- Van der Kloot W (1991) The regulation of quantal size. *Prog Neurobiol* 36:93–130. [CrossRef Medline](#)
- van Heesch F, Prins J, Konsman JP, Westphal KG, Olivier B, Kraneveld AD, Korte SM (2013) Lipopolysaccharide-induced anhedonia is abolished in male serotonin transporter knockout rats: an intracranial self-stimulation study. *Brain Behav Immun* 29:98–103. [CrossRef Medline](#)
- Vendruscolo LF, Roberts AJ (2014) Operant alcohol self-administration in dependent rats: focus on the vapor model. *Alcohol* 48:277–286. [CrossRef Medline](#)
- Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T (2011) IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. *Brain Behav Immun* 25:1281–1289. [CrossRef Medline](#)
- von Meyenburg C, Hrupka BH, Arsenijevic D, Schwartz GJ, Landmann R, Langhans W (2004) Role for CD14, TLR2, and TLR4 in bacterial product-induced anorexia. *Am J Physiol Regul Integr Comp Physiol* 287: R298–R305. [CrossRef Medline](#)

- Wang X, Zhang Y, Peng Y, Hutchinson MR, Rice KC, Yin H, Watkins LR (2016) Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as Toll-like receptor 4 antagonists. *Br J Pharmacol* 173:856–869. [CrossRef Medline](#)
- Wu X, Fu Y, Knott G, Lu J, Di Cristo G, Huang ZJ (2012a) GABA signaling promotes synapse elimination and axon pruning in developing cortical inhibitory interneurons. *J Neurosci* 32:331–343. [CrossRef Medline](#)
- Wu Y, Lousberg EL, Moldenhauer LM, Hayball JD, Collier JK, Rice KC, Watkins LR, Somogyi AA, Hutchinson MR (2012b) Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. *Br J Pharmacol* 165:1319–1329. [CrossRef Medline](#)
- Yang JC, Wu SC, Rau CS, Lu TH, Wu YC, Chen YC, Lin MW, Tzeng SL, Wu CJ, Hsieh CH (2014) Inhibition of the phosphoinositide 3-kinase pathway decreases innate resistance to lipopolysaccharide toxicity in TLR4 deficient mice. *J Biomed Sci* 21:20. [CrossRef Medline](#)
- Zhao Y, Weiss F, Zorrilla EP (2007) Remission and resurgence of anxiety-like behavior across protracted withdrawal stages in ethanol-dependent rats. *Alcohol Clin Exp Res* 31:1505–1515. [CrossRef Medline](#)
- Zou JY, Crews FT (2014) Release of neuronal HMGB1 by ethanol through decreased HDAC activity activates brain neuroimmune signaling. *PloS One* 9:e87915. [CrossRef Medline](#)